{"name":"Merck Sharp & Dohme LLC","slug":"merck-sharp-dohme-llc","ticker":"","exchange":"","domain":"mercksharpdohmellc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":23643200000,"revenueGrowth":-0.9,"grossMargin":0,"rdSpend":5139200000,"netIncome":7952300000,"cash":41749700000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2009"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":157,"colorKey":"immunology","drugs":[{"name":"Prandial insulin","genericName":"Prandial insulin","slug":"prandial-insulin","indication":"Other","status":"marketed"},{"name":"favezelimab/pembrolizumab","genericName":"favezelimab/pembrolizumab","slug":"favezelimab-pembrolizumab","indication":"Other","status":"phase_3"},{"name":"Comparator: Influenza Vaccine","genericName":"Comparator: Influenza Vaccine","slug":"comparator-influenza-vaccine","indication":"Seasonal influenza prevention in adults and children","status":"phase_3"},{"name":"LANTUS insulin","genericName":"LANTUS insulin","slug":"lantus-insulin","indication":"Other","status":"marketed"},{"name":"MK-1708","genericName":"MK-1708","slug":"mk-1708","indication":"Other","status":"phase_1"},{"name":"MK-4716","genericName":"MK-4716","slug":"mk-4716","indication":"Other","status":"phase_1"},{"name":"MK-8655","genericName":"MK-8655","slug":"mk-8655","indication":"Other","status":"phase_1"},{"name":"MK0822A","genericName":"MK0822A","slug":"mk0822a","indication":"Other","status":"phase_2"},{"name":"RotaTeq™ existing formulation","genericName":"RotaTeq™ existing formulation","slug":"rotateq-existing-formulation","indication":"Prevention of rotavirus gastroenteritis in infants and children","status":"phase_3"},{"name":"Supportive care measures","genericName":"Supportive care measures","slug":"supportive-care-measures","indication":"Other","status":"phase_3"},{"name":"ULO","genericName":"ULO","slug":"ulo","indication":"Chronic gout management and serum uric acid lowering","status":"marketed"},{"name":"V114 Medium Dose","genericName":"V114 Medium Dose","slug":"v114-medium-dose","indication":"Other","status":"phase_1"},{"name":"ZOSTAVAX™ (concomitant)","genericName":"ZOSTAVAX™ (concomitant)","slug":"zostavax-concomitant","indication":"Prevention of herpes zoster (shingles) in adults 50 years of age and older","status":"phase_3"},{"name":"rocuronium continuous infusion maintenance","genericName":"rocuronium continuous infusion maintenance","slug":"rocuronium-continuous-infusion-maintenance","indication":"Endotracheal intubation and maintenance of muscle relaxation during surgery","status":"phase_3"},{"name":"Atorvastatin and rosuvastatin oral solution","genericName":"Atorvastatin and rosuvastatin oral solution","slug":"atorvastatin-and-rosuvastatin-oral-solution","indication":"Other","status":"phase_1"},{"name":"Comparator: Aprepitant","genericName":"Comparator: Aprepitant","slug":"comparator-aprepitant","indication":"Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy","status":"phase_3"},{"name":"Comparator: Infanrix™","genericName":"Comparator: Infanrix™","slug":"comparator-infanrix","indication":"Prevention of diphtheria, tetanus, and pertussis in infants and children (primary series and boosters)","status":"marketed"},{"name":"Comparator: PedvaxHIB™","genericName":"Comparator: PedvaxHIB™","slug":"comparator-pedvaxhib","indication":"Prevention of invasive disease caused by Haemophilus influenzae type b in infants and children","status":"marketed"},{"name":"Comparator: Varicella Zoster Virus Vaccine","genericName":"Comparator: Varicella Zoster Virus Vaccine","slug":"comparator-varicella-zoster-virus-vaccine","indication":"Prevention of varicella (chickenpox)","status":"phase_3"},{"name":"DAPTACEL™","genericName":"DAPTACEL™","slug":"daptacel","indication":"Other","status":"marketed"},{"name":"DTP-IPV","genericName":"DTP-IPV","slug":"dtp-ipv","indication":"Other","status":"marketed"},{"name":"Donepepzil","genericName":"Donepepzil","slug":"donepepzil","indication":"Other","status":"discontinued"},{"name":"Epacadostat 100 mg","genericName":"Epacadostat 100 mg","slug":"epacadostat-100-mg","indication":"Other","status":"phase_1"},{"name":"Epinastine Nasal Spray","genericName":"Epinastine Nasal Spray","slug":"epinastine-nasal-spray","indication":"Allergic rhinitis","status":"phase_2"},{"name":"Experimental: V503","genericName":"Experimental: V503","slug":"experimental-v503","indication":"Other","status":"phase_3"},{"name":"Famotidine FCT","genericName":"Famotidine FCT","slug":"famotidine-fct","indication":"Other","status":"phase_1"},{"name":"Fludrocortisone/ Fludrocortisone acetate","genericName":"Fludrocortisone/ Fludrocortisone acetate","slug":"fludrocortisone-fludrocortisone-acetate","indication":"Adrenocortical insufficiency (Addison's disease)","status":"marketed"},{"name":"HBVAXPRO™","genericName":"HBVAXPRO™","slug":"hbvaxpro","indication":"Other","status":"marketed"},{"name":"MK-1167","genericName":"MK-1167","slug":"mk-1167","indication":"Other","status":"phase_2"},{"name":"MK-2060","genericName":"MK-2060","slug":"mk-2060","indication":"Other","status":"phase_2"},{"name":"MK-3120","genericName":"MK-3120","slug":"mk-3120","indication":"Other","status":"phase_1"},{"name":"MK-4830","genericName":"MK-4830","slug":"mk-4830","indication":"Other","status":"phase_2"},{"name":"MK-5172A","genericName":"MK-5172A","slug":"mk-5172a","indication":"Other","status":"marketed"},{"name":"MK-7288","genericName":"MK-7288","slug":"mk-7288","indication":"Other","status":"phase_1"},{"name":"MK-8521 150μg","genericName":"MK-8521 150μg","slug":"mk-8521-150-g","indication":"Other","status":"phase_1"},{"name":"MK0777","genericName":"MK0777","slug":"mk0777","indication":"Other","status":"phase_2"},{"name":"MK0826, /Duration of Treatment : 8 Weeks","genericName":"MK0826, /Duration of Treatment : 8 Weeks","slug":"mk0826-duration-of-treatment-8-weeks","indication":"Other","status":"phase_3"},{"name":"MK0991, caspofungin acetate","genericName":"MK0991, caspofungin acetate","slug":"mk0991-caspofungin-acetate","indication":"Invasive aspergillosis","status":"phase_2"},{"name":"Pataday","genericName":"Pataday","slug":"pataday","indication":"Allergic conjunctivitis","status":"marketed"},{"name":"Pembrolizumab Dose A","genericName":"Pembrolizumab Dose A","slug":"pembrolizumab-dose-a","indication":"Other","status":"phase_1"},{"name":"Placebo for lenvatinib","genericName":"Placebo for lenvatinib","slug":"placebo-for-lenvatinib","indication":"Control arm in Phase 3 clinical trial for lenvatinib","status":"phase_3"},{"name":"Placebo matched to MK-8527","genericName":"Placebo matched to MK-8527","slug":"placebo-matched-to-mk-8527","indication":"Other","status":"phase_3"},{"name":"Placebo to V920","genericName":"Placebo to V920","slug":"placebo-to-v920","indication":"HPV-related cervical intraepithelial neoplasia (CIN)","status":"phase_3"},{"name":"ProQuad®","genericName":"ProQuad®","slug":"proquad","indication":"Prevention of measles, mumps, rubella, and varicella in children aged 12 months and older","status":"marketed"},{"name":"RSV A Memphis 37b","genericName":"RSV A Memphis 37b","slug":"rsv-a-memphis-37b","indication":"Other","status":"phase_2"},{"name":"Raltegravir Film-coated Tablet","genericName":"Raltegravir Film-coated Tablet","slug":"raltegravir-film-coated-tablet","indication":"Other","status":"phase_2"},{"name":"Ridaforolimus 100 mg","genericName":"Ridaforolimus 100 mg","slug":"ridaforolimus-100-mg","indication":"Other","status":"phase_1"},{"name":"Rocuronium bromide (Org 9426)","genericName":"Rocuronium bromide (Org 9426)","slug":"rocuronium-bromide-org-9426","indication":"Endotracheal intubation","status":"phase_3"},{"name":"RotaTeq™ experimental formulation","genericName":"RotaTeq™ experimental formulation","slug":"rotateq-experimental-formulation","indication":"Prevention of rotavirus gastroenteritis in infants and young children","status":"phase_3"},{"name":"SCH 900636","genericName":"SCH 900636","slug":"sch-900636","indication":"Other","status":"phase_2"},{"name":"Saline placebo for pembrolizumab","genericName":"Saline placebo for pembrolizumab","slug":"saline-placebo-for-pembrolizumab","indication":"Control arm in pembrolizumab clinical trials (Phase 3)","status":"phase_3"},{"name":"Sandostatine®","genericName":"Sandostatine®","slug":"sandostatine","indication":"Other","status":"phase_1"},{"name":"Short ragweed pollen allergen extract","genericName":"Short ragweed pollen allergen extract","slug":"short-ragweed-pollen-allergen-extract","indication":"Treatment of short ragweed-induced allergic rhinitis with or without conjunctivitis symptoms","status":"phase_3"},{"name":"Sitagliptin phosphate anhydrous formulation","genericName":"Sitagliptin phosphate anhydrous formulation","slug":"sitagliptin-phosphate-anhydrous-formulation","indication":"Other","status":"phase_1"},{"name":"Treatment F","genericName":"Treatment F","slug":"treatment-f","indication":"Other","status":"marketed"},{"name":"V114, Aluminum Nonadjuvanted","genericName":"V114, Aluminum Nonadjuvanted","slug":"v114-aluminum-nonadjuvanted","indication":"Other","status":"phase_1"},{"name":"V116","genericName":"V116","slug":"v116","indication":"Prevention of group B Streptococcus (GBS) disease in pregnant women and neonates","status":"phase_3"},{"name":"V160 High Dose IM","genericName":"V160 High Dose IM","slug":"v160-high-dose-im","indication":"Other","status":"phase_1"},{"name":"V160 Maximum Dose IM","genericName":"V160 Maximum Dose IM","slug":"v160-maximum-dose-im","indication":"Other","status":"phase_1"},{"name":"V501","genericName":"V501","slug":"v501","indication":"Other","status":"marketed"},{"name":"V504","genericName":"V504","slug":"v504","indication":"Other","status":"phase_2"},{"name":"V512","genericName":"V512","slug":"v512","indication":"Other","status":"phase_1"},{"name":"V520","genericName":"V520","slug":"v520","indication":"Other","status":"phase_1"},{"name":"V920 Consistency Lot A","genericName":"V920 Consistency Lot A","slug":"v920-consistency-lot-a","indication":"Prevention of herpes zoster (shingles) in adults aged 50 years and older","status":"phase_3"},{"name":"V934-EP","genericName":"V934-EP","slug":"v934-ep","indication":"Other","status":"phase_1"},{"name":"V935","genericName":"V935","slug":"v935","indication":"Other","status":"phase_1"},{"name":"VARIVAX® PE34 Process","genericName":"VARIVAX® PE34 Process","slug":"varivax-pe34-process","indication":"Prevention of varicella (chickenpox)","status":"phase_3"},{"name":"VARIVAX™ New Seed Process","genericName":"VARIVAX™ New Seed Process","slug":"varivax-new-seed-process","indication":"Prevention of varicella (chickenpox) in children and adults","status":"phase_3"},{"name":"Vaniprevir 300 mg","genericName":"Vaniprevir 300 mg","slug":"vaniprevir-300-mg","indication":"Other","status":"phase_1"},{"name":"ZOSTAVAX™","genericName":"ZOSTAVAX™","slug":"zostavax","indication":"Other","status":"marketed"},{"name":"Zoster Vaccine, Live (AMP)","genericName":"Zoster Vaccine, Live (AMP)","slug":"zoster-vaccine-live-amp","indication":"Prevention of herpes zoster (shingles) in adults 50 years of age and older","status":"phase_3"},{"name":"[18F]MK-6240, ~185 MBq","genericName":"[18F]MK-6240, ~185 MBq","slug":"18f-mk-6240-185-mbq","indication":"Other","status":"phase_1"},{"name":"14^C-labeled ertugliflozin for oral use","genericName":"14^C-labeled ertugliflozin for oral use","slug":"14-c-labeled-ertugliflozin-for-oral-use","indication":"Other","status":"phase_1"},{"name":"89Zr-MK-4464","genericName":"89Zr-MK-4464","slug":"89zr-mk-4464","indication":"Other","status":"phase_1"},{"name":"AP23573","genericName":"AP23573","slug":"ap23573","indication":"Other","status":"phase_1"},{"name":"Antiemetic","genericName":"Antiemetic","slug":"antiemetic","indication":"Other","status":"marketed"},{"name":"Background ART Regimen","genericName":"Background ART Regimen","slug":"background-art-regimen","indication":"Other","status":"phase_2"},{"name":"Calcitriol Cream","genericName":"Calcitriol Cream","slug":"calcitriol-cream","indication":"Other","status":"marketed"},{"name":"Calderasib","genericName":"Calderasib","slug":"calderasib","indication":"Other","status":"phase_3"},{"name":"Calderasib OCT","genericName":"Calderasib OCT","slug":"calderasib-oct","indication":"Other","status":"phase_1"},{"name":"Carboplatin AUC6","genericName":"Carboplatin AUC6","slug":"carboplatin-auc6","indication":"Other","status":"phase_2"},{"name":"Comparator: M-M-R II","genericName":"Comparator: M-M-R II","slug":"comparator-m-m-r-ii","indication":"Prevention of measles, mumps, and rubella in children and adults","status":"phase_3"},{"name":"Comparator: MK0517","genericName":"Comparator: MK0517","slug":"comparator-mk0517","indication":"Chemotherapy-induced nausea and vomiting (CINV)","status":"phase_3"},{"name":"Comparator: Modified Process Vaccine","genericName":"Comparator: Modified Process Vaccine","slug":"comparator-modified-process-vaccine","indication":"Other","status":"phase_3"},{"name":"Comparator: Placebo matching RotaTeq™","genericName":"Comparator: Placebo matching RotaTeq™","slug":"comparator-placebo-matching-rotateq","indication":"Rotavirus gastroenteritis prevention (Phase 3 trial comparator)","status":"phase_3"},{"name":"Comparator: Placebo to aprepitant","genericName":"Comparator: Placebo to aprepitant","slug":"comparator-placebo-to-aprepitant","indication":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","status":"phase_3"},{"name":"Comparator: ProQuad™ (V221)","genericName":"Comparator: ProQuad™ (V221)","slug":"comparator-proquad-v221","indication":"Prevention of measles, mumps, rubella, and varicella in children and adults","status":"phase_3"},{"name":"Comparator: Tripedia","genericName":"Comparator: Tripedia","slug":"comparator-tripedia","indication":"Prevention of diphtheria, tetanus, and pertussis in infants and children","status":"phase_3"},{"name":"Comparator: Varivax","genericName":"Comparator: Varivax","slug":"comparator-varivax","indication":"Prevention of varicella (chickenpox) in children and adults","status":"phase_3"},{"name":"Comparator: fosaprepitant dimeglumine","genericName":"Comparator: fosaprepitant dimeglumine","slug":"comparator-fosaprepitant-dimeglumine","indication":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","status":"phase_3"},{"name":"Comparator: ondansetron IV","genericName":"Comparator: ondansetron IV","slug":"comparator-ondansetron-iv","indication":"Prevention of nausea and vomiting induced by chemotherapy","status":"phase_3"},{"name":"Dabigatran and pitavastatin oral solution","genericName":"Dabigatran and pitavastatin oral solution","slug":"dabigatran-and-pitavastatin-oral-solution","indication":"Other","status":"phase_1"},{"name":"Docetetaxel","genericName":"Docetetaxel","slug":"docetetaxel","indication":"Other","status":"phase_2"},{"name":"Doravine","genericName":"Doravine","slug":"doravine","indication":"Other","status":"phase_1"},{"name":"Dose-matched Placebo to Suvorexant","genericName":"Dose-matched Placebo to Suvorexant","slug":"dose-matched-placebo-to-suvorexant","indication":"Insomnia (sleep onset and/or sleep maintenance) — placebo control in phase 3 trials","status":"phase_3"},{"name":"EMEND","genericName":"EMEND","slug":"emend","indication":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","status":"marketed"},{"name":"Elestat","genericName":"Elestat","slug":"elestat","indication":"Other","status":"marketed"},{"name":"Emetogenic chemotherapy","genericName":"Emetogenic chemotherapy","slug":"emetogenic-chemotherapy","indication":"Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving emetogenic chemotherapy","status":"phase_3"},{"name":"Glimepiride 2 mg","genericName":"Glimepiride 2 mg","slug":"glimepiride-2-mg","indication":"Other","status":"marketed"},{"name":"Glimerpiride","genericName":"Glimerpiride","slug":"glimerpiride","indication":"Other","status":"phase_3"},{"name":"H1 Receptor Antagonist","genericName":"H1 Receptor Antagonist","slug":"h1-receptor-antagonist","indication":"Allergic rhinitis","status":"phase_3"},{"name":"H2 Receptor Antagonist","genericName":"H2 Receptor Antagonist","slug":"h2-receptor-antagonist","indication":"Peptic ulcer disease","status":"phase_3"},{"name":"Leader Antacid","genericName":"Leader Antacid","slug":"leader-antacid","indication":"Other","status":"marketed"},{"name":"M-M-RTM II","genericName":"M-M-RTM II","slug":"m-m-rtm-ii","indication":"Prevention of measles, mumps, and rubella in children and adults","status":"marketed"},{"name":"MK-0822","genericName":"MK-0822","slug":"mk-0822","indication":"Other","status":"phase_1"},{"name":"MK-0873 2% Cream","genericName":"MK-0873 2% Cream","slug":"mk-0873-2-cream","indication":"Other","status":"phase_1"},{"name":"MK-1006 FCT","genericName":"MK-1006 FCT","slug":"mk-1006-fct","indication":"Other","status":"phase_1"},{"name":"MK-1075","genericName":"MK-1075","slug":"mk-1075","indication":"Other","status":"phase_1"},{"name":"MK-2214","genericName":"MK-2214","slug":"mk-2214","indication":"Other","status":"phase_2"},{"name":"MK-4082","genericName":"MK-4082","slug":"mk-4082","indication":"Other","status":"phase_1"},{"name":"MK-4305 40 mg","genericName":"MK-4305 40 mg","slug":"mk-4305-40-mg","indication":"Other","status":"phase_1"},{"name":"MK-4618","genericName":"MK-4618","slug":"mk-4618","indication":"Other","status":"phase_1"},{"name":"MK-4646","genericName":"MK-4646","slug":"mk-4646","indication":"Other","status":"phase_1"},{"name":"MK-4700","genericName":"MK-4700","slug":"mk-4700","indication":"Other","status":"phase_1"},{"name":"MK-5478","genericName":"MK-5478","slug":"mk-5478","indication":"Other","status":"phase_1"},{"name":"MK-6837","genericName":"MK-6837","slug":"mk-6837","indication":"Other","status":"phase_1"},{"name":"MK-6916","genericName":"MK-6916","slug":"mk-6916","indication":"Other","status":"phase_1"},{"name":"MK-7252","genericName":"MK-7252","slug":"mk-7252","indication":"Other","status":"phase_1"},{"name":"MK-8150 100 mg","genericName":"MK-8150 100 mg","slug":"mk-8150-100-mg","indication":"Other","status":"phase_1"},{"name":"MK-8150 120 mg","genericName":"MK-8150 120 mg","slug":"mk-8150-120-mg","indication":"Other","status":"phase_1"},{"name":"MK-8150 160 mg","genericName":"MK-8150 160 mg","slug":"mk-8150-160-mg","indication":"Other","status":"phase_1"},{"name":"MK-8150 600 mg","genericName":"MK-8150 600 mg","slug":"mk-8150-600-mg","indication":"Other","status":"phase_1"},{"name":"MK-8266 BID, 1.8 mg","genericName":"MK-8266 BID, 1.8 mg","slug":"mk-8266-bid-1-8-mg","indication":"Other","status":"phase_1"},{"name":"MK-8266 TID, 2.4 mg","genericName":"MK-8266 TID, 2.4 mg","slug":"mk-8266-tid-2-4-mg","indication":"Other","status":"phase_1"},{"name":"MK-8504","genericName":"MK-8504","slug":"mk-8504","indication":"Other","status":"phase_1"},{"name":"MK-8507","genericName":"MK-8507","slug":"mk-8507","indication":"Other","status":"phase_1"},{"name":"MK-8558","genericName":"MK-8558","slug":"mk-8558","indication":"Other","status":"phase_1"},{"name":"MK-8616","genericName":"MK-8616","slug":"mk-8616","indication":"Other","status":"phase_2"},{"name":"MK-8931","genericName":"MK-8931","slug":"mk-8931","indication":"Other","status":"phase_1"},{"name":"MK0249","genericName":"MK0249","slug":"mk0249","indication":"Other","status":"phase_2"},{"name":"MK0364","genericName":"MK0364","slug":"mk0364","indication":"Other","status":"phase_2"},{"name":"MK0524","genericName":"MK0524","slug":"mk0524","indication":"Other","status":"phase_2"},{"name":"MK0752","genericName":"MK0752","slug":"mk0752","indication":"Other","status":"phase_1"},{"name":"MK0773","genericName":"MK0773","slug":"mk0773","indication":"Other","status":"phase_1"},{"name":"MK0826; ertapenem sodium","genericName":"MK0826; ertapenem sodium","slug":"mk0826-ertapenem-sodium","indication":"Other","status":"marketed"},{"name":"MK0869, aprepitant","genericName":"MK0869, aprepitant","slug":"mk0869-aprepitant","indication":"Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy","status":"phase_3"},{"name":"MK0974 Ethanolate formulation","genericName":"MK0974 Ethanolate formulation","slug":"mk0974-ethanolate-formulation","indication":"Other","status":"phase_1"},{"name":"MK8245","genericName":"MK8245","slug":"mk8245","indication":"Other","status":"phase_1"},{"name":"MMRV (2006 process)","genericName":"MMRV (2006 process)","slug":"mmrv-2006-process","indication":"Prevention of measles, mumps, rubella, and varicella in children aged 12 months and older","status":"phase_3"},{"name":"MMRV (AMP)","genericName":"MMRV (AMP)","slug":"mmrv-amp","indication":"Prevention of measles, mumps, rubella, and varicella in children","status":"phase_3"},{"name":"Matching Placebo for V114","genericName":"Matching Placebo for V114","slug":"matching-placebo-for-v114","indication":"Other","status":"phase_3"},{"name":"Matching Placebo for V116","genericName":"Matching Placebo for V116","slug":"matching-placebo-for-v116","indication":"Other","status":"phase_3"},{"name":"Matching placebo to dapagliflozin","genericName":"Matching placebo to dapagliflozin","slug":"matching-placebo-to-dapagliflozin","indication":"Other","status":"phase_3"},{"name":"Matching placebo to glimepiride","genericName":"Matching placebo to glimepiride","slug":"matching-placebo-to-glimepiride","indication":"Clinical trial comparator for glimepiride efficacy and safety studies","status":"marketed"},{"name":"Metformn","genericName":"Metformn","slug":"metformn","indication":"Other","status":"phase_2"},{"name":"NeisVac-C®","genericName":"NeisVac-C®","slug":"neisvac-c","indication":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C in infants, children, adolescents, and adults","status":"marketed"},{"name":"Normale Saline Solution","genericName":"Normale Saline Solution","slug":"normale-saline-solution","indication":"Fluid resuscitation and volume replacement in dehydration","status":"phase_3"},{"name":"Org 50081","genericName":"Org 50081","slug":"org-50081","indication":"Muscle wasting or sarcopenia (investigational)","status":"phase_3"},{"name":"PEG-IFN alfa-2b","genericName":"PEG-IFN alfa-2b","slug":"peg-ifn-alfa-2b","indication":"Other","status":"marketed"},{"name":"PENTACEL™","genericName":"PENTACEL™","slug":"pentacel","indication":"Other","status":"marketed"},{"name":"PLD, cyclophosphamide, trastuzumab, paclitaxel","genericName":"PLD, cyclophosphamide, trastuzumab, paclitaxel","slug":"pld-cyclophosphamide-trastuzumab-paclitaxel","indication":"Other","status":"phase_2"},{"name":"Pegylated Lyposomal Doxorubicin","genericName":"Pegylated Lyposomal Doxorubicin","slug":"pegylated-lyposomal-doxorubicin","indication":"Other","status":"phase_2"},{"name":"Pembrolizumab placebo (saline)","genericName":"Pembrolizumab placebo (saline)","slug":"pembrolizumab-placebo-saline","indication":"Control arm in pembrolizumab phase 3 clinical trials","status":"phase_3"},{"name":"Placebo - 0.9% w/v sodium chloride solution","genericName":"Placebo - 0.9% w/v sodium chloride solution","slug":"placebo-0-9-w-v-sodium-chloride-solution","indication":"Placebo control in Phase 3 clinical trials","status":"phase_3"},{"name":"Placebo for Aprepitant PFS","genericName":"Placebo for Aprepitant PFS","slug":"placebo-for-aprepitant-pfs","indication":"Control arm in clinical trials for aprepitant efficacy and safety evaluation","status":"phase_3"},{"name":"Placebo for Enlicitide","genericName":"Placebo for Enlicitide","slug":"placebo-for-enlicitide","indication":"Control arm in Phase 3 clinical trial for Enlicitide","status":"phase_3"},{"name":"Placebo for V110","genericName":"Placebo for V110","slug":"placebo-for-v110","indication":"Control arm in V110 clinical trial (indication for V110 unknown)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":38,"colorKey":"oncology","drugs":[{"name":"MK0557","genericName":"MK0557","slug":"mk0557","indication":"Obesity or overweight with weight-related comorbidities","status":"phase_3"},{"name":"Sitagliptin phosphate/metformin hydrochloride FDC","genericName":"Sitagliptin phosphate/metformin hydrochloride FDC","slug":"sitagliptin-phosphate-metformin-hydrochloride-fdc","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Glycemic Rescue 2","genericName":"Glycemic Rescue 2","slug":"glycemic-rescue-2","indication":"Type 2 diabetes mellitus (presumed, based on drug name and phase)","status":"phase_3"},{"name":"Comparator: glimepiride","genericName":"Comparator: glimepiride","slug":"comparator-glimepiride","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Comparator: glipizide","genericName":"Comparator: glipizide","slug":"comparator-glipizide","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Glimepiride Rescue Medication","genericName":"Glimepiride Rescue Medication","slug":"glimepiride-rescue-medication","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Glycemic Rescue","genericName":"Glycemic Rescue","slug":"glycemic-rescue","indication":"Acute severe hypoglycemia in diabetic patients","status":"phase_3"},{"name":"Glycemic Rescue 1","genericName":"Glycemic Rescue 1","slug":"glycemic-rescue-1","indication":"Acute hyperglycemia or glycemic rescue in diabetes","status":"phase_3"},{"name":"ISL","genericName":"ISL","slug":"isl","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"MK-0524B","genericName":"MK-0524B","slug":"mk-0524b","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Placebo to omarigliptin","genericName":"Placebo to omarigliptin","slug":"placebo-to-omarigliptin","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Sitagliptin plus metformin","genericName":"Sitagliptin plus metformin","slug":"sitagliptin-plus-metformin","indication":"Type 2 diabetes","status":"phase_3"},{"name":"V260","genericName":"V260","slug":"v260","indication":"Type 2 diabetes","status":"phase_3"},{"name":"sitagliptin (MK0431)","genericName":"sitagliptin (MK0431)","slug":"sitagliptin-mk0431","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Comparator: Antidiabetic Standard of Care","genericName":"Comparator: Antidiabetic Standard of Care","slug":"comparator-antidiabetic-standard-of-care","indication":"Type 2 diabetes mellitus (as standard-of-care comparator in phase 3 trials)","status":"phase_3"},{"name":"Comparator: Rosiglitazone","genericName":"Comparator: Rosiglitazone","slug":"comparator-rosiglitazone","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Comparator: Sitagliptin","genericName":"Comparator: Sitagliptin","slug":"comparator-sitagliptin","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Comparator: Sulfonylurea","genericName":"Comparator: Sulfonylurea","slug":"comparator-sulfonylurea","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Comparator: placebo metformin","genericName":"Comparator: placebo metformin","slug":"comparator-placebo-metformin","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Comparator: placebo to pioglitazone","genericName":"Comparator: placebo to pioglitazone","slug":"comparator-placebo-to-pioglitazone","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Comparator: placebo to sitagliptin","genericName":"Comparator: placebo to sitagliptin","slug":"comparator-placebo-to-sitagliptin","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Comparator: voglibose","genericName":"Comparator: voglibose","slug":"comparator-voglibose","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Glimepiride or gliclazide","genericName":"Glimepiride or gliclazide","slug":"glimepiride-or-gliclazide","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Insulin Glargine Rescue Medication","genericName":"Insulin Glargine Rescue Medication","slug":"insulin-glargine-rescue-medication","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"MK-1293","genericName":"MK-1293","slug":"mk-1293","indication":"Type 2 diabetes","status":"phase_3"},{"name":"MK-6072","genericName":"MK-6072","slug":"mk-6072","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"MK0524A, /Duration of Treatment : 4 Weeks","genericName":"MK0524A, /Duration of Treatment : 4 Weeks","slug":"mk0524a-duration-of-treatment-4-weeks","indication":"Dyslipidemia with low HDL-cholesterol and/or elevated triglycerides","status":"phase_3"},{"name":"Matching Placebo to Sita/Met FDC","genericName":"Matching Placebo to Sita/Met FDC","slug":"matching-placebo-to-sita-met-fdc","indication":"Treatment of type 2 diabetes","status":"phase_3"},{"name":"Matching placebo to omarigliptin","genericName":"Matching placebo to omarigliptin","slug":"matching-placebo-to-omarigliptin","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Matching placebo to pioglitazone","genericName":"Matching placebo to pioglitazone","slug":"matching-placebo-to-pioglitazone","indication":"Type 2 diabetes mellitus (placebo control in phase 3 trial)","status":"phase_3"},{"name":"Matching placebo to sitagliptin","genericName":"Matching placebo to sitagliptin","slug":"matching-placebo-to-sitagliptin","indication":"Control arm in phase 3 trial of sitagliptin for type 2 diabetes mellitus","status":"phase_3"},{"name":"Metformin - Rescue","genericName":"Metformin - Rescue","slug":"metformin-rescue","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Open-label Glimepiride","genericName":"Open-label Glimepiride","slug":"open-label-glimepiride","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Open-label Metformin","genericName":"Open-label Metformin","slug":"open-label-metformin","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Pioglitazone rescue therapy","genericName":"Pioglitazone rescue therapy","slug":"pioglitazone-rescue-therapy","indication":"Type 2 diabetes mellitus (rescue/add-on therapy)","status":"phase_3"},{"name":"Placebo for Glipizide","genericName":"Placebo for Glipizide","slug":"placebo-for-glipizide","indication":"Control arm in Phase 3 clinical trial for Glipizide efficacy in type 2 diabetes","status":"phase_3"},{"name":"Placebo for Rosuvastatin","genericName":"Placebo for Rosuvastatin","slug":"placebo-for-rosuvastatin","indication":"Hypercholesterolemia","status":"phase_3"},{"name":"Placebo for Sitagliptin","genericName":"Placebo for Sitagliptin","slug":"placebo-for-sitagliptin","indication":"Control arm in Phase 3 clinical trial for Sitagliptin (type 2 diabetes mellitus)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":37,"colorKey":"neuroscience","drugs":[{"name":"PCV15 - Part B","genericName":"PCV15 - Part B","slug":"pcv15-part-b","indication":"Prevention of invasive pneumococcal disease in adults aged 18 years and older","status":"phase_3"},{"name":"ATRIPLA^TM","genericName":"ATRIPLA^TM","slug":"atripla-tm","indication":"HIV-1 infection","status":"phase_2"},{"name":"AzaSite Eye Drops","genericName":"AzaSite Eye Drops","slug":"azasite-eye-drops","indication":"Bacterial conjunctivitis","status":"marketed"},{"name":"AzaSite®","genericName":"AzaSite®","slug":"azasite","indication":"Bacterial conjunctivitis","status":"marketed"},{"name":"Azithromycin Ophthalmic Solution, 1%","genericName":"Azithromycin Ophthalmic Solution, 1%","slug":"azithromycin-ophthalmic-solution-1","indication":"Bacterial conjunctivitis","status":"marketed"},{"name":"Boceprevir (BOC)","genericName":"Boceprevir (BOC)","slug":"boceprevir-boc","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1, in combination with peginterferon alfa and ribavirin","status":"phase_3"},{"name":"Comparator: Truvada","genericName":"Comparator: Truvada","slug":"comparator-truvada","indication":"HIV-1 infection treatment in combination with other antiretroviral agents","status":"phase_3"},{"name":"Comparator: VAQTA™","genericName":"Comparator: VAQTA™","slug":"comparator-vaqta","indication":"Prevention of hepatitis A virus infection in adults and children ≥12 months of age","status":"marketed"},{"name":"Comparator: ceftriaxone sodium","genericName":"Comparator: ceftriaxone sodium","slug":"comparator-ceftriaxone-sodium","indication":"Bacterial infections including meningitis, sepsis, and lower respiratory tract infections","status":"phase_3"},{"name":"Elbasvir Oral Granules","genericName":"Elbasvir Oral Granules","slug":"elbasvir-oral-granules","indication":"Chronic hepatitis C virus infection","status":"phase_2"},{"name":"Influenza A Virus","genericName":"Influenza A Virus","slug":"influenza-a-virus","indication":"Prevention of seasonal influenza A infection","status":"marketed"},{"name":"PIP/TAZ FDC","genericName":"PIP/TAZ FDC","slug":"pip-taz-fdc","indication":"Bacterial infections (broad-spectrum coverage for intra-abdominal, gynecological, skin, and respiratory tract infections)","status":"phase_3"},{"name":"Placebo to Reformulated Raltegravir","genericName":"Placebo to Reformulated Raltegravir","slug":"placebo-to-reformulated-raltegravir","indication":"HIV-1 infection in treatment-naive and treatment-experienced patients","status":"phase_3"},{"name":"Ribavirin (SCH 018908)","genericName":"Ribavirin (SCH 018908)","slug":"ribavirin-sch-018908","indication":"Chronic hepatitis C (in combination with interferon alfa or direct-acting antivirals)","status":"marketed"},{"name":"pneumococcal 23v polysaccharide vaccine","genericName":"pneumococcal 23v polysaccharide vaccine","slug":"pneumococcal-23v-polysaccharide-vaccine","indication":"Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes included in the vaccine","status":"phase_3"},{"name":"Adefovir dipivoxil (adefovir)","genericName":"Adefovir dipivoxil (adefovir)","slug":"adefovir-dipivoxil-adefovir","indication":"Chronic hepatitis B infection","status":"marketed"},{"name":"Amoxicillin/clavulunate potassium","genericName":"Amoxicillin/clavulunate potassium","slug":"amoxicillin-clavulunate-potassium","indication":"Bacterial infections caused by susceptible organisms including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media","status":"phase_3"},{"name":"Colistimethate sodium (CMS)","genericName":"Colistimethate sodium (CMS)","slug":"colistimethate-sodium-cms","indication":"Multidrug-resistant gram-negative bacterial infections","status":"phase_3"},{"name":"Comparator: Comparator: ENGERIX-B","genericName":"Comparator: Comparator: ENGERIX-B","slug":"comparator-comparator-engerix-b","indication":"Prevention of hepatitis B infection in infants, children, and adults","status":"phase_3"},{"name":"Comparator: ENGERIX-B™","genericName":"Comparator: ENGERIX-B™","slug":"comparator-engerix-b","indication":"Prevention of hepatitis B infection in infants, children, and adults","status":"phase_3"},{"name":"Comparator: Micafungin sodium","genericName":"Comparator: Micafungin sodium","slug":"comparator-micafungin-sodium","indication":"Candidemia and acute disseminated candidiasis","status":"phase_3"},{"name":"Comparator: Placebo to MK-0518","genericName":"Comparator: Placebo to MK-0518","slug":"comparator-placebo-to-mk-0518","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"Comparator: Placebo to efavirenz","genericName":"Comparator: Placebo to efavirenz","slug":"comparator-placebo-to-efavirenz","indication":"HIV-1 infection (as part of combination antiretroviral therapy)","status":"phase_3"},{"name":"Comparator: cefotetan","genericName":"Comparator: cefotetan","slug":"comparator-cefotetan","indication":"Surgical prophylaxis","status":"phase_3"},{"name":"Comparator: ceftriaxone + metronidazole","genericName":"Comparator: ceftriaxone + metronidazole","slug":"comparator-ceftriaxone-metronidazole","indication":"Intra-abdominal infections (polymicrobial)","status":"marketed"},{"name":"Comparator: efavirenz","genericName":"Comparator: efavirenz","slug":"comparator-efavirenz","indication":"HIV-1 infection (as part of combination antiretroviral therapy)","status":"phase_3"},{"name":"Cross-Over Boceprevir Treatment","genericName":"Cross-Over Boceprevir Treatment","slug":"cross-over-boceprevir-treatment","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1","status":"phase_3"},{"name":"Doravirine, Tenofovir, Lamivudine","genericName":"Doravirine, Tenofovir, Lamivudine","slug":"doravirine-tenofovir-lamivudine","indication":"HIV-1 infection in treatment-naïve adults","status":"marketed"},{"name":"Doravirine, Tenofovir, Lamivudine - Open-Label","genericName":"Doravirine, Tenofovir, Lamivudine - Open-Label","slug":"doravirine-tenofovir-lamivudine-open-label","indication":"Treatment of HIV-1 infection in adults with no antiretroviral treatment history or with viral suppression on a stable antiretroviral regimen for at least 6 months","status":"phase_2"},{"name":"Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate","genericName":"Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate","slug":"doravirine-lamivudine-tenofovir-disoproxil-fumarate","indication":"HIV-1 infection in treatment-naïve adults","status":"phase_3"},{"name":"IMI/REL FDC","genericName":"IMI/REL FDC","slug":"imi-rel-fdc","indication":"Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria","status":"phase_3"},{"name":"Letermovir intravenous","genericName":"Letermovir intravenous","slug":"letermovir-intravenous","indication":"Prevention of cytomegalovirus (CMV) infection in adult recipients of an allogeneic hematopoietic stem cell transplant","status":"phase_2"},{"name":"MK-0518","genericName":"MK-0518","slug":"mk-0518","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"MK-8591A","genericName":"MK-8591A","slug":"mk-8591a","indication":"HIV-1 infection (treatment-experienced and treatment-naive patients)","status":"phase_3"},{"name":"Modified Process Hepatitis B Vaccine","genericName":"Modified Process Hepatitis B Vaccine","slug":"modified-process-hepatitis-b-vaccine","indication":"Prevention of hepatitis B infection in infants, children, and adults","status":"phase_3"},{"name":"Oral Suspension Tedizolid Phosphate","genericName":"Oral Suspension Tedizolid Phosphate","slug":"oral-suspension-tedizolid-phosphate","indication":"Acute bacterial skin and skin structure infections (ABSSSI)","status":"marketed"},{"name":"Peginterferon alfa-2b (PEG2b)","genericName":"Peginterferon alfa-2b (PEG2b)","slug":"peginterferon-alfa-2b-peg2b","indication":"Chronic hepatitis C","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":30,"colorKey":"cardiovascular","drugs":[{"name":"Rescue medications for chemotherapy","genericName":"Rescue medications for chemotherapy","slug":"rescue-medications-for-chemotherapy","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"I-DXd","genericName":"I-DXd","slug":"i-dxd","indication":"Relapsed or refractory B-cell non-Hodgkin lymphoma","status":"phase_2"},{"name":"Leucovorin (or Levoleucovorin)","genericName":"Leucovorin (or Levoleucovorin)","slug":"leucovorin-or-levoleucovorin","indication":"Methotrexate toxicity rescue (high-dose methotrexate therapy)","status":"phase_3"},{"name":"Thyroid hormone","genericName":"Thyroid hormone","slug":"thyroid-hormone","indication":"Hypothyroidism","status":"marketed"},{"name":"Calogen®","genericName":"Calogen®","slug":"calogen","indication":"Nutritional support in patients with malnutrition or cachexia","status":"marketed"},{"name":"HER3-DXd","genericName":"HER3-DXd","slug":"her3-dxd","indication":"Breast cancer","status":"phase_2"},{"name":"Leucovorin/ levoleucovorin","genericName":"Leucovorin/ levoleucovorin","slug":"leucovorin-levoleucovorin","indication":"Metastatic colorectal cancer (in combination with fluorouracil)","status":"phase_3"},{"name":"MK-3415A","genericName":"MK-3415A","slug":"mk-3415a","indication":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)","status":"phase_3"},{"name":"MK-4280","genericName":"MK-4280","slug":"mk-4280","indication":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)","status":"phase_3"},{"name":"MK-4280A","genericName":"MK-4280A","slug":"mk-4280a","indication":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)","status":"phase_3"},{"name":"Pegylated filgrastim","genericName":"Pegylated filgrastim","slug":"pegylated-filgrastim","indication":"Chemotherapy-induced neutropenia in patients with non-myeloid malignancies","status":"phase_3"},{"name":"Carboplatin AUC2","genericName":"Carboplatin AUC2","slug":"carboplatin-auc2","indication":"Ovarian cancer","status":"phase_2"},{"name":"Cisplatin (as radiosensitizer)","genericName":"Cisplatin (as radiosensitizer)","slug":"cisplatin-as-radiosensitizer","indication":"Concurrent chemoradiation for locally advanced cancers (head and neck, cervical, lung, esophageal)","status":"phase_3"},{"name":"Comparator: Gardasil","genericName":"Comparator: Gardasil","slug":"comparator-gardasil","indication":"Prevention of cervical cancer caused by HPV types 16 and 18","status":"phase_3"},{"name":"Comparator: dexamethasone","genericName":"Comparator: dexamethasone","slug":"comparator-dexamethasone","indication":"Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)","status":"phase_3"},{"name":"Doxorubicin (A)","genericName":"Doxorubicin (A)","slug":"doxorubicin-a","indication":"Breast cancer","status":"phase_3"},{"name":"IV Tulisokibart","genericName":"IV Tulisokibart","slug":"iv-tulisokibart","indication":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)","status":"phase_3"},{"name":"Leucovorin/levofolinate calcium","genericName":"Leucovorin/levofolinate calcium","slug":"leucovorin-levofolinate-calcium","indication":"Metastatic colorectal cancer (in combination with 5-fluorouracil)","status":"phase_3"},{"name":"MK-3475A","genericName":"MK-3475A","slug":"mk-3475a","indication":"Advanced or metastatic melanoma","status":"phase_3"},{"name":"MK-8527","genericName":"MK-8527","slug":"mk-8527","indication":"Acute myeloid leukemia (AML) with TP53 mutations","status":"phase_3"},{"name":"MK0831","genericName":"MK0831","slug":"mk0831","indication":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)","status":"phase_3"},{"name":"Paclitaxel (X)","genericName":"Paclitaxel (X)","slug":"paclitaxel-x","indication":"Metastatic carcinoma of the ovary","status":"phase_3"},{"name":"Peginterferon alfa-2b (PEG)","genericName":"Peginterferon alfa-2b (PEG)","slug":"peginterferon-alfa-2b-peg","indication":"Chronic hepatitis C (in combination with ribavirin)","status":"phase_3"},{"name":"Pembrolizumab (K)","genericName":"Pembrolizumab (K)","slug":"pembrolizumab-k","indication":"Metastatic melanoma","status":"phase_3"},{"name":"Pembrolizumab Formulated with Berahyaluronidase Alfa","genericName":"Pembrolizumab Formulated with Berahyaluronidase Alfa","slug":"pembrolizumab-formulated-with-berahyaluronidase-alfa","indication":"Melanoma (advanced or metastatic)","status":"phase_3"},{"name":"Pembrolizumab IV","genericName":"Pembrolizumab IV","slug":"pembrolizumab-iv","indication":"Metastatic melanoma","status":"phase_3"},{"name":"Pembrolizumab SC","genericName":"Pembrolizumab SC","slug":"pembrolizumab-sc","indication":"Metastatic non-small cell lung cancer (NSCLC)","status":"phase_3"},{"name":"Pembrolizumab/Quavonlimab","genericName":"Pembrolizumab/Quavonlimab","slug":"pembrolizumab-quavonlimab","indication":"Locally advanced or metastatic non-small cell lung cancer","status":"phase_3"},{"name":"Pembrolizumab/Vibostolimab","genericName":"Pembrolizumab/Vibostolimab","slug":"pembrolizumab-vibostolimab","indication":"Advanced or metastatic melanoma","status":"phase_3"},{"name":"Pembrolizumab/Vibostolimab Co-Formulation","genericName":"Pembrolizumab/Vibostolimab Co-Formulation","slug":"pembrolizumab-vibostolimab-co-formulation","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":15,"colorKey":"rare","drugs":[{"name":"Extended-release niacin (ERN)","genericName":"Extended-release niacin (ERN)","slug":"extended-release-niacin-ern","indication":"Dyslipidemia / hyperlipidemia (elevated triglycerides and/or low HDL cholesterol)","status":"phase_3"},{"name":"MINTOX® Maximum Strength","genericName":"MINTOX® Maximum Strength","slug":"mintox-maximum-strength","indication":"Heartburn relief","status":"marketed"},{"name":"MK0803, lovastatin","genericName":"MK0803, lovastatin","slug":"mk0803-lovastatin","indication":"Hypercholesterolemia","status":"phase_3"},{"name":"Placebo to losartan potassium","genericName":"Placebo to losartan potassium","slug":"placebo-to-losartan-potassium","indication":"Hypertension","status":"phase_3"},{"name":"Antihyperglycemic Medication","genericName":"Antihyperglycemic Medication","slug":"antihyperglycemic-medication","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Background PAH Therapy","genericName":"Background PAH Therapy","slug":"background-pah-therapy","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"Comparator: Losartan","genericName":"Comparator: Losartan","slug":"comparator-losartan","indication":"Hypertension","status":"phase_3"},{"name":"Comparator: dorzolamide hydrochloride","genericName":"Comparator: dorzolamide hydrochloride","slug":"comparator-dorzolamide-hydrochloride","indication":"Glaucoma","status":"phase_3"},{"name":"Comparator: niacin","genericName":"Comparator: niacin","slug":"comparator-niacin","indication":"Dyslipidemia; elevated triglycerides and/or low HDL cholesterol","status":"phase_3"},{"name":"Comparator: niacin + laropiprant","genericName":"Comparator: niacin + laropiprant","slug":"comparator-niacin-laropiprant","indication":"Dyslipidemia in patients at risk for cardiovascular disease","status":"phase_3"},{"name":"Comparator: timolol","genericName":"Comparator: timolol","slug":"comparator-timolol","indication":"Glaucoma","status":"phase_3"},{"name":"DOR/ISL","genericName":"DOR/ISL","slug":"dor-isl","indication":"Open-angle glaucoma","status":"phase_3"},{"name":"ER-niacin","genericName":"ER-niacin","slug":"er-niacin","indication":"Dyslipidemia; elevated triglycerides and low HDL cholesterol in patients at risk for cardiovascular disease","status":"phase_3"},{"name":"L50/H12.5","genericName":"L50/H12.5","slug":"l50-h12-5","indication":"Hypertension","status":"phase_3"},{"name":"L50/H12.5/A5","genericName":"L50/H12.5/A5","slug":"l50-h12-5-a5","indication":"Hypertension in patients requiring triple antihypertensive therapy","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"respiratory","drugs":[{"name":"Dexamethasone (or equivalent)","genericName":"Dexamethasone (or equivalent)","slug":"dexamethasone-or-equivalent","indication":"Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)","status":"phase_3"},{"name":"Pneumovax™23","genericName":"Pneumovax™23","slug":"pneumovax23","indication":"Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis) caused by Streptococcus pneumoniae serotypes included in the vaccine","status":"marketed"},{"name":"Comparator: Adacel™","genericName":"Comparator: Adacel™","slug":"comparator-adacel","indication":"Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults","status":"phase_3"},{"name":"Comparator: Comvax","genericName":"Comparator: Comvax","slug":"comparator-comvax","indication":"Immunization against hepatitis B virus infection","status":"phase_3"},{"name":"Comparator: Infanrix(tm) Hexa","genericName":"Comparator: Infanrix(tm) Hexa","slug":"comparator-infanrix-tm-hexa","indication":"Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children","status":"phase_3"},{"name":"Comparator: valdecoxib","genericName":"Comparator: valdecoxib","slug":"comparator-valdecoxib","indication":"Osteoarthritis","status":"phase_3"},{"name":"Comparator: vancomycin","genericName":"Comparator: vancomycin","slug":"comparator-vancomycin","indication":"Serious infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)","status":"phase_3"},{"name":"IV golimumab","genericName":"IV golimumab","slug":"iv-golimumab","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Letermovir IV","genericName":"Letermovir IV","slug":"letermovir-iv","indication":"CMV prophylaxis in CMV-seronegative recipients of allogeneic hematopoietic stem cell transplant from CMV-seropositive donors","status":"phase_3"},{"name":"MK0966 / Duration of Treatment: 1 Days","genericName":"MK0966 / Duration of Treatment: 1 Days","slug":"mk0966-duration-of-treatment-1-days","indication":"Acute pain","status":"phase_3"},{"name":"MK0966; rofecoxib","genericName":"MK0966; rofecoxib","slug":"mk0966-rofecoxib","indication":"Osteoarthritis","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"infectious","drugs":[{"name":"Acetaminophen (or equivalent)","genericName":"Acetaminophen (or equivalent)","slug":"acetaminophen-or-equivalent","indication":"Mild to moderate pain","status":"phase_3"},{"name":"Comparator: oxycodone and acetaminophen","genericName":"Comparator: oxycodone and acetaminophen","slug":"comparator-oxycodone-and-acetaminophen","indication":"Moderate to moderately severe acute or chronic pain","status":"phase_3"},{"name":"DOR","genericName":"DOR","slug":"dor","indication":"Chronic pain conditions","status":"marketed"},{"name":"MK-1084","genericName":"MK-1084","slug":"mk-1084","indication":"Chronic pain conditions (investigational)","status":"phase_3"},{"name":"PPI","genericName":"PPI","slug":"ppi","indication":"Gastroesophageal reflux disease (GERD)","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"metabolic","drugs":[{"name":"Placebo to Telcagepant","genericName":"Placebo to Telcagepant","slug":"placebo-to-telcagepant","indication":"Acute treatment of migraine attacks with or without aura","status":"phase_3"},{"name":"Comparator: paroxetine HCL","genericName":"Comparator: paroxetine HCL","slug":"comparator-paroxetine-hcl","indication":"Major depressive disorder","status":"phase_3"},{"name":"Enclitide Chloride","genericName":"Enclitide Chloride","slug":"enclitide-chloride","indication":"Treatment of chemotherapy-induced neuropathic pain","status":"phase_2"},{"name":"Neostigmine + Glycopyrrolate","genericName":"Neostigmine + Glycopyrrolate","slug":"neostigmine-glycopyrrolate","indication":"Reversal of neuromuscular blockade induced by non-depolarizing neuromuscular blocking agents","status":"marketed"},{"name":"PegIFN-2b","genericName":"PegIFN-2b","slug":"pegifn-2b","indication":"Chronic hepatitis C (in combination with ribavirin)","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"Comparator: fluticasone","genericName":"Comparator: fluticasone","slug":"comparator-fluticasone","indication":"Asthma maintenance therapy","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"dermatology","drugs":[{"name":"INS365 Ophthalmic Solution","genericName":"INS365 Ophthalmic Solution","slug":"ins365-ophthalmic-solution","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"}]}],"pipeline":[{"name":"MK0557","genericName":"MK0557","slug":"mk0557","phase":"phase_3","mechanism":"MK0557 is a ghrelin receptor (GHS-R1a) antagonist that blocks the orexigenic signaling of ghrelin to reduce appetite and food intake.","indications":["Obesity or overweight with weight-related comorbidities"],"catalyst":""},{"name":"Prandial insulin","genericName":"Prandial insulin","slug":"prandial-insulin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rescue medications for chemotherapy","genericName":"Rescue medications for chemotherapy","slug":"rescue-medications-for-chemotherapy","phase":"phase_3","mechanism":"This drug works by inhibiting the activity of the PD-1 receptor, allowing the immune system to attack cancer cells.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma","Urothelial carcinoma","Melanoma","Renal cell carcinoma"],"catalyst":""},{"name":"Sitagliptin phosphate/metformin hydrochloride FDC","genericName":"Sitagliptin phosphate/metformin hydrochloride FDC","slug":"sitagliptin-phosphate-metformin-hydrochloride-fdc","phase":"marketed","mechanism":"This combination drug inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels while metformin reduces hepatic glucose production and improves insulin sensitivity.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"favezelimab/pembrolizumab","genericName":"favezelimab/pembrolizumab","slug":"favezelimab-pembrolizumab","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Comparator: Influenza Vaccine","genericName":"Comparator: Influenza Vaccine","slug":"comparator-influenza-vaccine","phase":"phase_3","mechanism":"Influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains, providing protection against infection.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"Glycemic Rescue 2","genericName":"Glycemic Rescue 2","slug":"glycemic-rescue-2","phase":"phase_3","mechanism":"Glycemic Rescue 2 is an investigational agent designed to improve blood glucose control in patients with diabetes through an undisclosed mechanism.","indications":["Type 2 diabetes mellitus (presumed, based on drug name and phase)"],"catalyst":""},{"name":"I-DXd","genericName":"I-DXd","slug":"i-dxd","phase":"phase_2","mechanism":"Targeting CD22 with antibody-drug conjugate","indications":["Relapsed or refractory B-cell non-Hodgkin lymphoma"],"catalyst":""},{"name":"LANTUS insulin","genericName":"LANTUS insulin","slug":"lantus-insulin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Leucovorin (or Levoleucovorin)","genericName":"Leucovorin (or Levoleucovorin)","slug":"leucovorin-or-levoleucovorin","phase":"phase_3","mechanism":"Leucovorin is a reduced form of folic acid that replenishes intracellular folate pools and enhances the efficacy of antimetabolite chemotherapy agents.","indications":["Methotrexate toxicity rescue (high-dose methotrexate therapy)","Potentiation of fluorouracil in colorectal cancer and other solid tumors","Megaloblastic anemia due to folate deficiency"],"catalyst":""},{"name":"MK-1708","genericName":"MK-1708","slug":"mk-1708","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-4716","genericName":"MK-4716","slug":"mk-4716","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8655","genericName":"MK-8655","slug":"mk-8655","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0822A","genericName":"MK0822A","slug":"mk0822a","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PCV15 - Part B","genericName":"PCV15 - Part B","slug":"pcv15-part-b","phase":"phase_3","mechanism":"PCV15 is a pneumococcal conjugate vaccine that stimulates immune responses against 15 serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier.","indications":["Prevention of invasive pneumococcal disease in adults aged 18 years and older","Prevention of pneumococcal pneumonia in adults"],"catalyst":""},{"name":"RotaTeq™ existing formulation","genericName":"RotaTeq™ existing formulation","slug":"rotateq-existing-formulation","phase":"phase_3","mechanism":"RotaTeq is a live attenuated rotavirus vaccine that stimulates immune responses to prevent rotavirus gastroenteritis.","indications":["Prevention of rotavirus gastroenteritis in infants and children"],"catalyst":""},{"name":"Supportive care measures","genericName":"Supportive care measures","slug":"supportive-care-measures","phase":"phase_3","mechanism":"Supportive care measures provide symptomatic relief and management of treatment-related side effects rather than direct therapeutic intervention.","indications":[],"catalyst":""},{"name":"Thyroid hormone","genericName":"Thyroid hormone","slug":"thyroid-hormone","phase":"marketed","mechanism":"Thyroid hormone replaces or supplements endogenous thyroid hormones (T3 and T4) to restore normal metabolic function in hypothyroid patients.","indications":["Hypothyroidism","Thyroid cancer suppression therapy","Myxedema coma"],"catalyst":""},{"name":"ULO","genericName":"ULO","slug":"ulo","phase":"marketed","mechanism":"ULO is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption.","indications":["Chronic gout management and serum uric acid lowering"],"catalyst":""},{"name":"V114 Medium Dose","genericName":"V114 Medium Dose","slug":"v114-medium-dose","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ZOSTAVAX™ (concomitant)","genericName":"ZOSTAVAX™ (concomitant)","slug":"zostavax-concomitant","phase":"phase_3","mechanism":"ZOSTAVAX is a live attenuated vaccine that stimulates an immune response against the varicella-zoster virus.","indications":["Prevention of herpes zoster (shingles) in adults 50 years of age and older"],"catalyst":""},{"name":"rocuronium continuous infusion maintenance","genericName":"rocuronium continuous infusion maintenance","slug":"rocuronium-continuous-infusion-maintenance","phase":"phase_3","mechanism":"Rocuronium acts as a competitive antagonist at the nicotinic acetylcholine receptor, preventing acetylcholine from binding and thereby inhibiting muscle contraction.","indications":["Endotracheal intubation and maintenance of muscle relaxation during surgery"],"catalyst":""},{"name":"ATRIPLA^TM","genericName":"ATRIPLA^TM","slug":"atripla-tm","phase":"phase_2","mechanism":"Non-nucleoside reverse transcriptase inhibitor","indications":["HIV-1 infection"],"catalyst":""},{"name":"Acetaminophen (or equivalent)","genericName":"Acetaminophen (or equivalent)","slug":"acetaminophen-or-equivalent","phase":"phase_3","mechanism":"Acetaminophen reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system.","indications":["Mild to moderate pain","Fever reduction"],"catalyst":""},{"name":"Atorvastatin and rosuvastatin oral solution","genericName":"Atorvastatin and rosuvastatin oral solution","slug":"atorvastatin-and-rosuvastatin-oral-solution","phase":"phase_1","mechanism":"Inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, reducing LDL cholesterol production in the liver.","indications":[],"catalyst":""},{"name":"AzaSite Eye Drops","genericName":"AzaSite Eye Drops","slug":"azasite-eye-drops","phase":"marketed","mechanism":"AzaSite is an azithromycin ophthalmic suspension that reduces bacterial load and inflammatory mediators in the eye to treat bacterial conjunctivitis and meibomian gland dysfunction.","indications":["Bacterial conjunctivitis","Meibomian gland dysfunction (dry eye disease)"],"catalyst":""},{"name":"AzaSite®","genericName":"AzaSite®","slug":"azasite","phase":"marketed","mechanism":"AzaSite is an azithromycin ophthalmic suspension that reduces bacterial load and inflammatory mediators in the eye to treat bacterial conjunctivitis and meibomian gland dysfunction.","indications":["Bacterial conjunctivitis","Meibomian gland dysfunction (dry eye disease)"],"catalyst":""},{"name":"Azithromycin Ophthalmic Solution, 1%","genericName":"Azithromycin Ophthalmic Solution, 1%","slug":"azithromycin-ophthalmic-solution-1","phase":"marketed","mechanism":"Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby killing or stopping the growth of susceptible bacteria.","indications":["Bacterial conjunctivitis","Bacterial keratitis"],"catalyst":""},{"name":"Boceprevir (BOC)","genericName":"Boceprevir (BOC)","slug":"boceprevir-boc","phase":"phase_3","mechanism":"Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral protein processing and replication.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1, in combination with peginterferon alfa and ribavirin"],"catalyst":""},{"name":"Calogen®","genericName":"Calogen®","slug":"calogen","phase":"marketed","mechanism":"Calogen is a high-calorie, high-fat oral nutritional supplement that provides concentrated energy to support weight maintenance and nutritional status in patients with increased caloric requirements.","indications":["Nutritional support in patients with malnutrition or cachexia","Caloric supplementation in patients with increased energy requirements","Nutritional support in cancer patients, post-surgical patients, and those with chronic disease"],"catalyst":""},{"name":"Comparator: Aprepitant","genericName":"Comparator: Aprepitant","slug":"comparator-aprepitant","phase":"phase_3","mechanism":"Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent nausea and vomiting.","indications":["Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy","Post-operative nausea and vomiting (PONV) prevention"],"catalyst":""},{"name":"Comparator: Infanrix™","genericName":"Comparator: Infanrix™","slug":"comparator-infanrix","phase":"marketed","mechanism":"Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.","indications":["Prevention of diphtheria, tetanus, and pertussis in infants and children (primary series and boosters)"],"catalyst":""},{"name":"Comparator: PedvaxHIB™","genericName":"Comparator: PedvaxHIB™","slug":"comparator-pedvaxhib","phase":"marketed","mechanism":"PedvaxHIB is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by presenting the bacterial polysaccharide capsule linked to a protein carrier.","indications":["Prevention of invasive disease caused by Haemophilus influenzae type b in infants and children"],"catalyst":""},{"name":"Comparator: Truvada","genericName":"Comparator: Truvada","slug":"comparator-truvada","phase":"phase_3","mechanism":"Truvada is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that blocks HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection treatment in combination with other antiretroviral agents","Pre-exposure prophylaxis (PrEP) for HIV-1 prevention in high-risk individuals"],"catalyst":""},{"name":"Comparator: VAQTA™","genericName":"Comparator: VAQTA™","slug":"comparator-vaqta","phase":"marketed","mechanism":"VAQTA is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.","indications":["Prevention of hepatitis A virus infection in adults and children ≥12 months of age"],"catalyst":""},{"name":"Comparator: Varicella Zoster Virus Vaccine","genericName":"Comparator: Varicella Zoster Virus Vaccine","slug":"comparator-varicella-zoster-virus-vaccine","phase":"phase_3","mechanism":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against varicella zoster virus, preventing chickenpox and herpes zoster infection.","indications":["Prevention of varicella (chickenpox)","Prevention of herpes zoster (shingles) and post-herpetic neuralgia"],"catalyst":""},{"name":"Comparator: ceftriaxone sodium","genericName":"Comparator: ceftriaxone sodium","slug":"comparator-ceftriaxone-sodium","phase":"phase_3","mechanism":"Ceftriaxone sodium is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","indications":["Bacterial infections including meningitis, sepsis, and lower respiratory tract infections","Surgical prophylaxis","Gonorrhea and other sexually transmitted infections"],"catalyst":""},{"name":"Comparator: glimepiride","genericName":"Comparator: glimepiride","slug":"comparator-glimepiride","phase":"marketed","mechanism":"Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Comparator: glipizide","genericName":"Comparator: glipizide","slug":"comparator-glipizide","phase":"phase_3","mechanism":"Glipizide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"DAPTACEL™","genericName":"DAPTACEL™","slug":"daptacel","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"DTP-IPV","genericName":"DTP-IPV","slug":"dtp-ipv","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Dexamethasone (or equivalent)","genericName":"Dexamethasone (or equivalent)","slug":"dexamethasone-or-equivalent","phase":"phase_3","mechanism":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.","indications":["Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)","Cerebral edema and increased intracranial pressure","Adrenocortical insufficiency","Severe allergic reactions","Certain hematologic malignancies (as adjunctive therapy)"],"catalyst":""},{"name":"Donepepzil","genericName":"Donepepzil","slug":"donepepzil","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Elbasvir Oral Granules","genericName":"Elbasvir Oral Granules","slug":"elbasvir-oral-granules","phase":"phase_2","mechanism":"Inhibits NS5A protein of hepatitis C virus","indications":["Chronic hepatitis C virus infection"],"catalyst":""},{"name":"Epacadostat 100 mg","genericName":"Epacadostat 100 mg","slug":"epacadostat-100-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Epinastine Nasal Spray","genericName":"Epinastine Nasal Spray","slug":"epinastine-nasal-spray","phase":"phase_2","mechanism":"Epinastine is a selective histamine H1-receptor antagonist that blocks the action of histamine on nasal mucosa, reducing symptoms of allergic rhinitis.","indications":["Allergic rhinitis"],"catalyst":""},{"name":"Experimental: V503","genericName":"Experimental: V503","slug":"experimental-v503","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Extended-release niacin (ERN)","genericName":"Extended-release niacin (ERN)","slug":"extended-release-niacin-ern","phase":"phase_3","mechanism":"Extended-release niacin increases HDL cholesterol and reduces triglycerides and LDL cholesterol by modulating lipid metabolism.","indications":["Dyslipidemia / hyperlipidemia (elevated triglycerides and/or low HDL cholesterol)","Cardiovascular risk reduction in patients with established coronary artery disease"],"catalyst":""},{"name":"Famotidine FCT","genericName":"Famotidine FCT","slug":"famotidine-fct","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fludrocortisone/ Fludrocortisone acetate","genericName":"Fludrocortisone/ Fludrocortisone acetate","slug":"fludrocortisone-fludrocortisone-acetate","phase":"marketed","mechanism":"Fludrocortisone is a synthetic corticosteroid that acts as a mineralocorticoid receptor agonist, increasing sodium reabsorption and potassium excretion in the kidneys to regulate fluid and electrolyte balance.","indications":["Adrenocortical insufficiency (Addison's disease)","Salt-wasting syndrome","Orthostatic hypotension","Hyponatremia"],"catalyst":""},{"name":"Glimepiride Rescue Medication","genericName":"Glimepiride Rescue Medication","slug":"glimepiride-rescue-medication","phase":"phase_3","mechanism":"Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Glycemic Rescue","genericName":"Glycemic Rescue","slug":"glycemic-rescue","phase":"phase_3","mechanism":"Glycemic Rescue is a glucose-stabilizing agent designed to rapidly restore blood glucose levels in acute hypoglycemic episodes.","indications":["Acute severe hypoglycemia in diabetic patients"],"catalyst":""},{"name":"Glycemic Rescue 1","genericName":"Glycemic Rescue 1","slug":"glycemic-rescue-1","phase":"phase_3","mechanism":"Glycemic Rescue 1 is designed to rapidly restore blood glucose control in acute hyperglycemic states.","indications":["Acute hyperglycemia or glycemic rescue in diabetes"],"catalyst":""},{"name":"HBVAXPRO™","genericName":"HBVAXPRO™","slug":"hbvaxpro","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"HER3-DXd","genericName":"HER3-DXd","slug":"her3-dxd","phase":"phase_2","mechanism":"HER3-DXd is a HER3-targeting antibody-drug conjugate.","indications":["Breast cancer","Gastric cancer"],"catalyst":""},{"name":"ISL","genericName":"ISL","slug":"isl","phase":"marketed","mechanism":"ISL is an insulin secretagogue that stimulates pancreatic beta cells to release insulin in response to glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Influenza A Virus","genericName":"Influenza A Virus","slug":"influenza-a-virus","phase":"marketed","mechanism":"This is not a drug but a pathogenic virus; Merck manufactures vaccines and antivirals against Influenza A Virus.","indications":["Prevention of seasonal influenza A infection","Treatment of acute influenza A infection"],"catalyst":""},{"name":"Leucovorin/ levoleucovorin","genericName":"Leucovorin/ levoleucovorin","slug":"leucovorin-levoleucovorin","phase":"phase_3","mechanism":"Leucovorin and levoleucovorin are reduced forms of folic acid that enhance the activity of antimetabolite chemotherapy drugs by providing essential one-carbon units for nucleotide synthesis.","indications":["Metastatic colorectal cancer (in combination with fluorouracil)","Methotrexate toxicity rescue","Advanced gastric cancer (in combination with fluorouracil and cisplatin)"],"catalyst":""},{"name":"MINTOX® Maximum Strength","genericName":"MINTOX® Maximum Strength","slug":"mintox-maximum-strength","phase":"marketed","mechanism":"MINTOX® Maximum Strength is an antacid that neutralizes stomach acid to relieve heartburn and indigestion.","indications":["Heartburn relief","Indigestion","Acid reflux"],"catalyst":""},{"name":"MK-0524B","genericName":"MK-0524B","slug":"mk-0524b","phase":"phase_3","mechanism":"MK-0524B is a glucagon receptor antagonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"MK-1167","genericName":"MK-1167","slug":"mk-1167","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-2060","genericName":"MK-2060","slug":"mk-2060","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MK-3120","genericName":"MK-3120","slug":"mk-3120","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MK-3415A","genericName":"MK-3415A","slug":"mk-3415a","phase":"phase_3","mechanism":"MK-3415A is a monoclonal antibody that targets and inhibits OX40, a costimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.","indications":["Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"MK-4280","genericName":"MK-4280","slug":"mk-4280","phase":"phase_3","mechanism":"MK-4280 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells to the tumor microenvironment.","indications":["Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"MK-4280A","genericName":"MK-4280A","slug":"mk-4280a","phase":"phase_3","mechanism":"MK-4280A is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of regulatory T cells and other immune cells to the tumor microenvironment.","indications":["Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"MK-4830","genericName":"MK-4830","slug":"mk-4830","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MK-5172A","genericName":"MK-5172A","slug":"mk-5172a","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-7288","genericName":"MK-7288","slug":"mk-7288","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8521 150μg","genericName":"MK-8521 150μg","slug":"mk-8521-150-g","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0777","genericName":"MK0777","slug":"mk0777","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0803, lovastatin","genericName":"MK0803, lovastatin","slug":"mk0803-lovastatin","phase":"phase_3","mechanism":"Lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","indications":["Hypercholesterolemia","Primary prevention of coronary heart disease"],"catalyst":""},{"name":"MK0826, /Duration of Treatment : 8 Weeks","genericName":"MK0826, /Duration of Treatment : 8 Weeks","slug":"mk0826-duration-of-treatment-8-weeks","phase":"phase_3","mechanism":"MK0826 is a selective inhibitor of a specific molecular target being evaluated in phase 3 clinical trials.","indications":[],"catalyst":""},{"name":"MK0991, caspofungin acetate","genericName":"MK0991, caspofungin acetate","slug":"mk0991-caspofungin-acetate","phase":"phase_2","mechanism":"Inhibits the synthesis of beta-1,3-D-glucan, a critical component of fungal cell walls.","indications":["Invasive aspergillosis","Candidemia","Esophageal candidiasis"],"catalyst":""},{"name":"PIP/TAZ FDC","genericName":"PIP/TAZ FDC","slug":"pip-taz-fdc","phase":"phase_3","mechanism":"PIP/TAZ is a fixed-dose combination of piperacillin (a broad-spectrum beta-lactam antibiotic) and tazobactam (a beta-lactamase inhibitor) that works together to kill bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.","indications":["Bacterial infections (broad-spectrum coverage for intra-abdominal, gynecological, skin, and respiratory tract infections)"],"catalyst":""},{"name":"Pataday","genericName":"Pataday","slug":"pataday","phase":"marketed","mechanism":"Histamine H1 receptor, Histamine H1 receptor","indications":["Allergic conjunctivitis","Allergic rhinitis","Seasonal allergic rhinitis"],"catalyst":""},{"name":"Pegylated filgrastim","genericName":"Pegylated filgrastim","slug":"pegylated-filgrastim","phase":"phase_3","mechanism":"Pegylated filgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) that stimulates the production and release of neutrophils from bone marrow to reduce infection risk in chemotherapy patients.","indications":["Chemotherapy-induced neutropenia in patients with non-myeloid malignancies","Reduction of infection risk in cancer patients receiving myelosuppressive chemotherapy"],"catalyst":""},{"name":"Pembrolizumab Dose A","genericName":"Pembrolizumab Dose A","slug":"pembrolizumab-dose-a","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Placebo for lenvatinib","genericName":"Placebo for lenvatinib","slug":"placebo-for-lenvatinib","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trial for lenvatinib"],"catalyst":""},{"name":"Placebo matched to MK-8527","genericName":"Placebo matched to MK-8527","slug":"placebo-matched-to-mk-8527","phase":"phase_3","mechanism":"This is a placebo control arm and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo to Reformulated Raltegravir","genericName":"Placebo to Reformulated Raltegravir","slug":"placebo-to-reformulated-raltegravir","phase":"phase_3","mechanism":"Raltegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA.","indications":["HIV-1 infection in treatment-naive and treatment-experienced patients"],"catalyst":""},{"name":"Placebo to Telcagepant","genericName":"Placebo to Telcagepant","slug":"placebo-to-telcagepant","phase":"phase_3","mechanism":"Telcagepant is a calcitonin gene-related peptide receptor antagonist.","indications":["Acute treatment of migraine attacks with or without aura"],"catalyst":""},{"name":"Placebo to V920","genericName":"Placebo to V920","slug":"placebo-to-v920","phase":"phase_3","mechanism":"V920 is a therapeutic vaccine designed to stimulate immune responses against human papillomavirus (HPV) infection.","indications":["HPV-related cervical intraepithelial neoplasia (CIN)","HPV-related oropharyngeal or anogenital lesions"],"catalyst":""},{"name":"Placebo to losartan potassium","genericName":"Placebo to losartan potassium","slug":"placebo-to-losartan-potassium","phase":"phase_3","mechanism":"Losartan potassium is an angiotensin II receptor antagonist that blocks the action of angiotensin II at its receptor in the blood vessels, causing them to relax and dilate, which lowers blood pressure and reduces the workload on the heart.","indications":["Hypertension","Diabetic nephropathy"],"catalyst":""},{"name":"Placebo to omarigliptin","genericName":"Placebo to omarigliptin","slug":"placebo-to-omarigliptin","phase":"phase_3","mechanism":"Omarigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to stimulate insulin secretion and reduce glucagon in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Pneumovax™23","genericName":"Pneumovax™23","slug":"pneumovax23","phase":"marketed","mechanism":"Pneumovax 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae bacteria.","indications":["Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis) caused by Streptococcus pneumoniae serotypes included in the vaccine","Prophylaxis in adults aged 50 years and older","Prophylaxis in high-risk populations including those with chronic diseases, immunocompromised states, or asplenia"],"catalyst":""},{"name":"ProQuad®","genericName":"ProQuad®","slug":"proquad","phase":"marketed","mechanism":"ProQuad is a live attenuated combination vaccine that stimulates immune response against measles, mumps, rubella, and varicella viruses.","indications":["Prevention of measles, mumps, rubella, and varicella in children aged 12 months and older"],"catalyst":""},{"name":"RSV A Memphis 37b","genericName":"RSV A Memphis 37b","slug":"rsv-a-memphis-37b","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Raltegravir Film-coated Tablet","genericName":"Raltegravir Film-coated Tablet","slug":"raltegravir-film-coated-tablet","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ribavirin (SCH 018908)","genericName":"Ribavirin (SCH 018908)","slug":"ribavirin-sch-018908","phase":"marketed","mechanism":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate pools and viral polymerase activity.","indications":["Chronic hepatitis C (in combination with interferon alfa or direct-acting antivirals)","Severe respiratory syncytial virus (RSV) infection","Hemorrhagic fever with renal syndrome","Lassa fever"],"catalyst":""},{"name":"Ridaforolimus 100 mg","genericName":"Ridaforolimus 100 mg","slug":"ridaforolimus-100-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rocuronium bromide (Org 9426)","genericName":"Rocuronium bromide (Org 9426)","slug":"rocuronium-bromide-org-9426","phase":"phase_3","mechanism":"Rocuronium bromide is a non-depolarizing neuromuscular blocking agent that competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction.","indications":["Endotracheal intubation","Surgical procedures requiring muscle relaxation"],"catalyst":""},{"name":"RotaTeq™ experimental formulation","genericName":"RotaTeq™ experimental formulation","slug":"rotateq-experimental-formulation","phase":"phase_3","mechanism":"RotaTeq is a live attenuated rotavirus vaccine that stimulates immune responses against rotavirus to prevent gastroenteritis.","indications":["Prevention of rotavirus gastroenteritis in infants and young children"],"catalyst":""},{"name":"SCH 900636","genericName":"SCH 900636","slug":"sch-900636","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Saline placebo for pembrolizumab","genericName":"Saline placebo for pembrolizumab","slug":"saline-placebo-for-pembrolizumab","phase":"phase_3","mechanism":"Saline placebo is an inert control substance with no active pharmacological mechanism.","indications":["Control arm in pembrolizumab clinical trials (Phase 3)"],"catalyst":""},{"name":"Sandostatine®","genericName":"Sandostatine®","slug":"sandostatine","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Short ragweed pollen allergen extract","genericName":"Short ragweed pollen allergen extract","slug":"short-ragweed-pollen-allergen-extract","phase":"phase_3","mechanism":"Short ragweed pollen allergen extract works by desensitizing patients to short ragweed pollen through subcutaneous injections.","indications":["Treatment of short ragweed-induced allergic rhinitis with or without conjunctivitis symptoms"],"catalyst":""},{"name":"Sitagliptin phosphate anhydrous formulation","genericName":"Sitagliptin phosphate anhydrous formulation","slug":"sitagliptin-phosphate-anhydrous-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sitagliptin plus metformin","genericName":"Sitagliptin plus metformin","slug":"sitagliptin-plus-metformin","phase":"phase_3","mechanism":"Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, enhancing glucose-dependent insulin secretion, and metformin, a biguanide, decreases hepatic glucose production and increases insulin sensitivity.","indications":["Type 2 diabetes","Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes"],"catalyst":""},{"name":"Treatment F","genericName":"Treatment F","slug":"treatment-f","phase":"marketed","mechanism":"Treatment F is not a recognized pharmaceutical product identifier in standard drug databases.","indications":[],"catalyst":""},{"name":"V114, Aluminum Nonadjuvanted","genericName":"V114, Aluminum Nonadjuvanted","slug":"v114-aluminum-nonadjuvanted","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"V116","genericName":"V116","slug":"v116","phase":"phase_3","mechanism":"V116 is a monoclonal antibody that targets group B Streptococcus (GBS) to enhance immune recognition and clearance of the pathogen.","indications":["Prevention of group B Streptococcus (GBS) disease in pregnant women and neonates"],"catalyst":""},{"name":"V160 High Dose IM","genericName":"V160 High Dose IM","slug":"v160-high-dose-im","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"V160 Maximum Dose IM","genericName":"V160 Maximum Dose IM","slug":"v160-maximum-dose-im","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"V260","genericName":"V260","slug":"v260","phase":"phase_3","mechanism":"V260 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"V501","genericName":"V501","slug":"v501","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"V504","genericName":"V504","slug":"v504","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"V512","genericName":"V512","slug":"v512","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"V520","genericName":"V520","slug":"v520","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"V920 Consistency Lot A","genericName":"V920 Consistency Lot A","slug":"v920-consistency-lot-a","phase":"phase_3","mechanism":"V920 is a vaccine candidate designed to stimulate immune responses against varicella-zoster virus (VZV) to prevent herpes zoster and post-herpetic neuralgia.","indications":["Prevention of herpes zoster (shingles) in adults aged 50 years and older","Prevention of post-herpetic neuralgia in adults aged 50 years and older"],"catalyst":""},{"name":"V934-EP","genericName":"V934-EP","slug":"v934-ep","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"V935","genericName":"V935","slug":"v935","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"VARIVAX® PE34 Process","genericName":"VARIVAX® PE34 Process","slug":"varivax-pe34-process","phase":"phase_3","mechanism":"VARIVAX PE34 Process is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox and herpes zoster infection.","indications":["Prevention of varicella (chickenpox)","Prevention of herpes zoster (shingles)"],"catalyst":""},{"name":"VARIVAX™ New Seed Process","genericName":"VARIVAX™ New Seed Process","slug":"varivax-new-seed-process","phase":"phase_3","mechanism":"VARIVAX is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox infection.","indications":["Prevention of varicella (chickenpox) in children and adults"],"catalyst":""},{"name":"Vaniprevir 300 mg","genericName":"Vaniprevir 300 mg","slug":"vaniprevir-300-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZOSTAVAX™","genericName":"ZOSTAVAX™","slug":"zostavax","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Zoster Vaccine, Live (AMP)","genericName":"Zoster Vaccine, Live (AMP)","slug":"zoster-vaccine-live-amp","phase":"phase_3","mechanism":"The Zoster Vaccine, Live (AMP) works by stimulating the body's immune system to produce a specific response against the varicella-zoster virus.","indications":["Prevention of herpes zoster (shingles) in adults 50 years of age and older"],"catalyst":""},{"name":"[18F]MK-6240, ~185 MBq","genericName":"[18F]MK-6240, ~185 MBq","slug":"18f-mk-6240-185-mbq","phase":"phase_1","mechanism":"A fluorine-18 labeled PET radiotracer that binds to aggregated tau protein deposits in the brain, enabling visualization of neurofibrillary tangles.","indications":[],"catalyst":""},{"name":"pneumococcal 23v polysaccharide vaccine","genericName":"pneumococcal 23v polysaccharide vaccine","slug":"pneumococcal-23v-polysaccharide-vaccine","phase":"phase_3","mechanism":"This vaccine stimulates the body's immune response to produce antibodies against pneumococcal serotypes.","indications":["Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes included in the vaccine"],"catalyst":""},{"name":"sitagliptin (MK0431)","genericName":"sitagliptin (MK0431)","slug":"sitagliptin-mk0431","phase":"phase_3","mechanism":"Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which is involved in the inactivation of incretin hormones.","indications":["Type 2 diabetes mellitus","Diabetic nephropathy"],"catalyst":""},{"name":"14^C-labeled ertugliflozin for oral use","genericName":"14^C-labeled ertugliflozin for oral use","slug":"14-c-labeled-ertugliflozin-for-oral-use","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"89Zr-MK-4464","genericName":"89Zr-MK-4464","slug":"89zr-mk-4464","phase":"phase_1","mechanism":"A zirconium-89 labeled PET imaging tracer that binds to a specific molecular target to enable visualization and quantification via positron emission tomography.","indications":[],"catalyst":""},{"name":"AP23573","genericName":"AP23573","slug":"ap23573","phase":"phase_1","mechanism":"AP23573 inhibits mTOR (mechanistic target of rapamycin), blocking signals that promote cancer cell growth and survival.","indications":[],"catalyst":""},{"name":"Adefovir dipivoxil (adefovir)","genericName":"Adefovir dipivoxil (adefovir)","slug":"adefovir-dipivoxil-adefovir","phase":"marketed","mechanism":"Adefovir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase activity in hepatitis B virus.","indications":["Chronic hepatitis B infection"],"catalyst":""},{"name":"Amoxicillin/clavulunate potassium","genericName":"Amoxicillin/clavulunate potassium","slug":"amoxicillin-clavulunate-potassium","phase":"phase_3","mechanism":"Amoxicillin/clavulanate is a beta-lactam antibiotic combination that kills bacteria by inhibiting cell wall synthesis, with clavulanate protecting amoxicillin from degradation by bacterial beta-lactamases.","indications":["Bacterial infections caused by susceptible organisms including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media"],"catalyst":""},{"name":"Antiemetic","genericName":"Antiemetic","slug":"antiemetic","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Antihyperglycemic Medication","genericName":"Antihyperglycemic Medication","slug":"antihyperglycemic-medication","phase":"marketed","mechanism":"This drug reduces blood glucose by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidney, allowing excess glucose to be excreted in urine.","indications":["Type 2 diabetes mellitus","Heart failure with reduced ejection fraction","Chronic kidney disease"],"catalyst":""},{"name":"Background ART Regimen","genericName":"Background ART Regimen","slug":"background-art-regimen","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Background PAH Therapy","genericName":"Background PAH Therapy","slug":"background-pah-therapy","phase":"phase_3","mechanism":"Background PAH Therapy refers to foundational pulmonary arterial hypertension treatment, typically involving vasodilators and/or endothelin receptor antagonists to reduce pulmonary vascular resistance.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"Calcitriol Cream","genericName":"Calcitriol Cream","slug":"calcitriol-cream","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Calderasib","genericName":"Calderasib","slug":"calderasib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Calderasib OCT","genericName":"Calderasib OCT","slug":"calderasib-oct","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Carboplatin AUC2","genericName":"Carboplatin AUC2","slug":"carboplatin-auc2","phase":"phase_2","mechanism":"Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription.","indications":["Ovarian cancer","Breast cancer","Lung cancer"],"catalyst":""},{"name":"Carboplatin AUC6","genericName":"Carboplatin AUC6","slug":"carboplatin-auc6","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cisplatin (as radiosensitizer)","genericName":"Cisplatin (as radiosensitizer)","slug":"cisplatin-as-radiosensitizer","phase":"phase_3","mechanism":"Cisplatin acts as a radiosensitizer by forming DNA adducts that enhance the cytotoxic effects of ionizing radiation, making cancer cells more susceptible to radiation-induced damage.","indications":["Concurrent chemoradiation for locally advanced cancers (head and neck, cervical, lung, esophageal)"],"catalyst":""},{"name":"Colistimethate sodium (CMS)","genericName":"Colistimethate sodium (CMS)","slug":"colistimethate-sodium-cms","phase":"phase_3","mechanism":"Colistimethate sodium is a prodrug that is hydrolyzed to colistin, which disrupts bacterial cell membranes by binding to lipopolysaccharides and causing cell lysis.","indications":["Multidrug-resistant gram-negative bacterial infections","Cystic fibrosis-associated Pseudomonas aeruginosa infections"],"catalyst":""},{"name":"Comparator: Adacel™","genericName":"Comparator: Adacel™","slug":"comparator-adacel","phase":"phase_3","mechanism":"Adacel is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis.","indications":["Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults"],"catalyst":""},{"name":"Comparator: Antidiabetic Standard of Care","genericName":"Comparator: Antidiabetic Standard of Care","slug":"comparator-antidiabetic-standard-of-care","phase":"phase_3","mechanism":"This is a comparator arm representing standard-of-care antidiabetic therapy used as a control reference in clinical trials, not a specific drug with a single mechanism.","indications":["Type 2 diabetes mellitus (as standard-of-care comparator in phase 3 trials)"],"catalyst":""},{"name":"Comparator: Comparator: ENGERIX-B","genericName":"Comparator: Comparator: ENGERIX-B","slug":"comparator-comparator-engerix-b","phase":"phase_3","mechanism":"ENGERIX-B is a hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg).","indications":["Prevention of hepatitis B infection in infants, children, and adults","Post-exposure prophylaxis for hepatitis B"],"catalyst":""},{"name":"Comparator: Comvax","genericName":"Comparator: Comvax","slug":"comparator-comvax","phase":"phase_3","mechanism":"Comvax is a combination vaccine that provides immunization against hepatitis B virus and Haemophilus influenzae type b (Hib) by stimulating the immune system to produce protective antibodies against both pathogens.","indications":["Immunization against hepatitis B virus infection","Immunization against Haemophilus influenzae type b (Hib) infection"],"catalyst":""},{"name":"Comparator: ENGERIX-B™","genericName":"Comparator: ENGERIX-B™","slug":"comparator-engerix-b","phase":"phase_3","mechanism":"ENGERIX-B is a recombinant hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection.","indications":["Prevention of hepatitis B infection in infants, children, and adults","Post-exposure prophylaxis for hepatitis B"],"catalyst":""},{"name":"Comparator: Gardasil","genericName":"Comparator: Gardasil","slug":"comparator-gardasil","phase":"phase_3","mechanism":"Gardasil is a recombinant quadrivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 6, 11, 16, and 18.","indications":["Prevention of cervical cancer caused by HPV types 16 and 18","Prevention of genital warts caused by HPV types 6 and 11","Prevention of anal, vulvar, and vaginal cancers caused by HPV types 16 and 18"],"catalyst":""},{"name":"Comparator: Infanrix(tm) Hexa","genericName":"Comparator: Infanrix(tm) Hexa","slug":"comparator-infanrix-tm-hexa","phase":"phase_3","mechanism":"Infanrix Hexa is a combination vaccine that stimulates the immune system to produce antibodies against six infectious diseases by presenting inactivated or toxoid antigens.","indications":["Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children"],"catalyst":""},{"name":"Comparator: Losartan","genericName":"Comparator: Losartan","slug":"comparator-losartan","phase":"phase_3","mechanism":"Losartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.","indications":["Hypertension","Diabetic nephropathy in patients with type 2 diabetes","Heart failure with reduced ejection fraction","Post-myocardial infarction"],"catalyst":""},{"name":"Comparator: M-M-R II","genericName":"Comparator: M-M-R II","slug":"comparator-m-m-r-ii","phase":"phase_3","mechanism":"M-M-R II is a live attenuated viral vaccine that stimulates immune response against measles, mumps, and rubella by introducing weakened forms of these viruses.","indications":["Prevention of measles, mumps, and rubella in children and adults"],"catalyst":""},{"name":"Comparator: MK0517","genericName":"Comparator: MK0517","slug":"comparator-mk0517","phase":"phase_3","mechanism":"MK0517 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.","indications":["Chemotherapy-induced nausea and vomiting (CINV)"],"catalyst":""},{"name":"Comparator: Micafungin sodium","genericName":"Comparator: Micafungin sodium","slug":"comparator-micafungin-sodium","phase":"phase_3","mechanism":"Micafungin sodium inhibits fungal cell wall synthesis by targeting 1,3-beta-D-glucan synthase, leading to fungal cell death.","indications":["Candidemia and acute disseminated candidiasis","Esophageal candidiasis","Prophylaxis of Candida infections in hematopoietic stem cell transplant recipients","Aspergillus infections (invasive aspergillosis)"],"catalyst":""},{"name":"Comparator: Modified Process Vaccine","genericName":"Comparator: Modified Process Vaccine","slug":"comparator-modified-process-vaccine","phase":"phase_3","mechanism":"A modified process vaccine that stimulates the immune system to recognize and respond to specific disease antigens through an altered manufacturing or formulation approach.","indications":[],"catalyst":""},{"name":"Comparator: Placebo matching RotaTeq™","genericName":"Comparator: Placebo matching RotaTeq™","slug":"comparator-placebo-matching-rotateq","phase":"phase_3","mechanism":"This is a placebo comparator arm in a RotaTeq clinical trial, not an active drug.","indications":["Rotavirus gastroenteritis prevention (Phase 3 trial comparator)"],"catalyst":""},{"name":"Comparator: Placebo to MK-0518","genericName":"Comparator: Placebo to MK-0518","slug":"comparator-placebo-to-mk-0518","phase":"phase_3","mechanism":"MK-0518 is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Comparator: Placebo to aprepitant","genericName":"Comparator: Placebo to aprepitant","slug":"comparator-placebo-to-aprepitant","phase":"phase_3","mechanism":"Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.","indications":["Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","Prevention of postoperative nausea and vomiting (PONV)"],"catalyst":""},{"name":"Comparator: Placebo to efavirenz","genericName":"Comparator: Placebo to efavirenz","slug":"comparator-placebo-to-efavirenz","phase":"phase_3","mechanism":"Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection (as part of combination antiretroviral therapy)"],"catalyst":""},{"name":"Comparator: ProQuad™ (V221)","genericName":"Comparator: ProQuad™ (V221)","slug":"comparator-proquad-v221","phase":"phase_3","mechanism":"ProQuad is a live attenuated combination vaccine that stimulates immune response against measles, mumps, rubella, and varicella viruses.","indications":["Prevention of measles, mumps, rubella, and varicella in children and adults"],"catalyst":""},{"name":"Comparator: Rosiglitazone","genericName":"Comparator: Rosiglitazone","slug":"comparator-rosiglitazone","phase":"phase_3","mechanism":"Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose levels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Comparator: Sitagliptin","genericName":"Comparator: Sitagliptin","slug":"comparator-sitagliptin","phase":"phase_3","mechanism":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Comparator: Sulfonylurea","genericName":"Comparator: Sulfonylurea","slug":"comparator-sulfonylurea","phase":"marketed","mechanism":"Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Comparator: Tripedia","genericName":"Comparator: Tripedia","slug":"comparator-tripedia","phase":"phase_3","mechanism":"Tripedia is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.","indications":["Prevention of diphtheria, tetanus, and pertussis in infants and children"],"catalyst":""},{"name":"Comparator: Varivax","genericName":"Comparator: Varivax","slug":"comparator-varivax","phase":"phase_3","mechanism":"Varivax is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox infection.","indications":["Prevention of varicella (chickenpox) in children and adults"],"catalyst":""},{"name":"Comparator: cefotetan","genericName":"Comparator: cefotetan","slug":"comparator-cefotetan","phase":"phase_3","mechanism":"Cefotetan is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","indications":["Surgical prophylaxis","Mixed aerobic-anaerobic infections","Gynecological infections","Intra-abdominal infections"],"catalyst":""},{"name":"Comparator: ceftriaxone + metronidazole","genericName":"Comparator: ceftriaxone + metronidazole","slug":"comparator-ceftriaxone-metronidazole","phase":"marketed","mechanism":"This is a fixed-dose combination of two antibiotics: ceftriaxone (a third-generation cephalosporin) inhibits bacterial cell wall synthesis, while metronidazole is a nitroimidazole that disrupts anaerobic bacterial DNA.","indications":["Intra-abdominal infections (polymicrobial)","Gynecological infections","Anaerobic bacterial infections"],"catalyst":""},{"name":"Comparator: dexamethasone","genericName":"Comparator: dexamethasone","slug":"comparator-dexamethasone","phase":"phase_3","mechanism":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.","indications":["Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)","Cerebral edema and increased intracranial pressure","Severe allergic reactions and anaphylaxis","Adrenocortical insufficiency","Supportive care in cancer therapy (chemotherapy-induced nausea and vomiting, prevention of hypersensitivity reactions)"],"catalyst":""},{"name":"Comparator: dorzolamide hydrochloride","genericName":"Comparator: dorzolamide hydrochloride","slug":"comparator-dorzolamide-hydrochloride","phase":"phase_3","mechanism":"Dorzolamide hydrochloride inhibits carbonic anhydrase II in the eye, reducing aqueous humor production and lowering intraocular pressure.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Comparator: efavirenz","genericName":"Comparator: efavirenz","slug":"comparator-efavirenz","phase":"phase_3","mechanism":"Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection (as part of combination antiretroviral therapy)"],"catalyst":""},{"name":"Comparator: fluticasone","genericName":"Comparator: fluticasone","slug":"comparator-fluticasone","phase":"phase_3","mechanism":"Fluticasone is a corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing immune cell activation and inflammatory mediator release.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Comparator: fosaprepitant dimeglumine","genericName":"Comparator: fosaprepitant dimeglumine","slug":"comparator-fosaprepitant-dimeglumine","phase":"phase_3","mechanism":"Fosaprepitant dimeglumine is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.","indications":["Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","Prevention of postoperative nausea and vomiting (PONV)"],"catalyst":""},{"name":"Comparator: niacin","genericName":"Comparator: niacin","slug":"comparator-niacin","phase":"phase_3","mechanism":"Niacin (vitamin B3) raises HDL cholesterol and lowers triglycerides and LDL cholesterol by inhibiting hepatic VLDL production and increasing apolipoprotein A-I.","indications":["Dyslipidemia; elevated triglycerides and/or low HDL cholesterol","Cardiovascular risk reduction in patients with established coronary artery disease"],"catalyst":""},{"name":"Comparator: niacin + laropiprant","genericName":"Comparator: niacin + laropiprant","slug":"comparator-niacin-laropiprant","phase":"phase_3","mechanism":"Niacin raises HDL cholesterol and lowers triglycerides, while laropiprant blocks the prostaglandin D2 receptor to reduce niacin-induced flushing.","indications":["Dyslipidemia in patients at risk for cardiovascular disease"],"catalyst":""},{"name":"Comparator: ondansetron IV","genericName":"Comparator: ondansetron IV","slug":"comparator-ondansetron-iv","phase":"phase_3","mechanism":"Ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.","indications":["Prevention of nausea and vomiting induced by chemotherapy","Prevention of postoperative nausea and vomiting","Prevention of radiation-induced nausea and vomiting"],"catalyst":""},{"name":"Comparator: oxycodone and acetaminophen","genericName":"Comparator: oxycodone and acetaminophen","slug":"comparator-oxycodone-and-acetaminophen","phase":"phase_3","mechanism":"This is a fixed-dose combination of oxycodone (a mu-opioid receptor agonist) and acetaminophen (a non-opioid analgesic) that provides pain relief through dual mechanisms.","indications":["Moderate to moderately severe acute or chronic pain"],"catalyst":""},{"name":"Comparator: paroxetine HCL","genericName":"Comparator: paroxetine HCL","slug":"comparator-paroxetine-hcl","phase":"phase_3","mechanism":"Paroxetine HCl selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.","indications":["Major depressive disorder","Generalized anxiety disorder","Panic disorder","Obsessive-compulsive disorder","Post-traumatic stress disorder"],"catalyst":""},{"name":"Comparator: placebo metformin","genericName":"Comparator: placebo metformin","slug":"comparator-placebo-metformin","phase":"phase_3","mechanism":"Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Comparator: placebo to pioglitazone","genericName":"Comparator: placebo to pioglitazone","slug":"comparator-placebo-to-pioglitazone","phase":"phase_3","mechanism":"Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose levels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Comparator: placebo to sitagliptin","genericName":"Comparator: placebo to sitagliptin","slug":"comparator-placebo-to-sitagliptin","phase":"phase_3","mechanism":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Comparator: timolol","genericName":"Comparator: timolol","slug":"comparator-timolol","phase":"phase_3","mechanism":"Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Comparator: valdecoxib","genericName":"Comparator: valdecoxib","slug":"comparator-valdecoxib","phase":"phase_3","mechanism":"Valdecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain.","indications":["Osteoarthritis","Rheumatoid arthritis","Acute pain","Dysmenorrhea"],"catalyst":""},{"name":"Comparator: vancomycin","genericName":"Comparator: vancomycin","slug":"comparator-vancomycin","phase":"phase_3","mechanism":"Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.","indications":["Serious infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)","Clostridium difficile-associated diarrhea and colitis","Endocarditis","Septicemia and other serious gram-positive infections"],"catalyst":""},{"name":"Comparator: voglibose","genericName":"Comparator: voglibose","slug":"comparator-voglibose","phase":"phase_3","mechanism":"Voglibose is an alpha-glucosidase inhibitor that slows the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose levels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Cross-Over Boceprevir Treatment","genericName":"Cross-Over Boceprevir Treatment","slug":"cross-over-boceprevir-treatment","phase":"phase_3","mechanism":"Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral replication by preventing the cleavage of HCV polyproteins.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1"],"catalyst":""},{"name":"DOR","genericName":"DOR","slug":"dor","phase":"marketed","mechanism":"DOR is a delta opioid receptor agonist that binds to and activates delta opioid receptors in the central and peripheral nervous system.","indications":["Chronic pain conditions"],"catalyst":""},{"name":"DOR/ISL","genericName":"DOR/ISL","slug":"dor-isl","phase":"phase_3","mechanism":"DOR/ISL is a combination of dorzolamide (a carbonic anhydrase inhibitor) and islatamide (a prostaglandin analog) that reduces intraocular pressure through dual mechanisms.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Dabigatran and pitavastatin oral solution","genericName":"Dabigatran and pitavastatin oral solution","slug":"dabigatran-and-pitavastatin-oral-solution","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Docetetaxel","genericName":"Docetetaxel","slug":"docetetaxel","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Doravine","genericName":"Doravine","slug":"doravine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Doravirine, Tenofovir, Lamivudine","genericName":"Doravirine, Tenofovir, Lamivudine","slug":"doravirine-tenofovir-lamivudine","phase":"marketed","mechanism":"This combination inhibits HIV reverse transcriptase and integrase to block viral replication and reduce viral load in HIV-infected patients.","indications":["HIV-1 infection in treatment-naïve adults","HIV-1 infection in treatment-experienced patients (with specific resistance profiles)"],"catalyst":""},{"name":"Doravirine, Tenofovir, Lamivudine - Open-Label","genericName":"Doravirine, Tenofovir, Lamivudine - Open-Label","slug":"doravirine-tenofovir-lamivudine-open-label","phase":"phase_2","mechanism":"Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), while Tenofovir and Lamivudine are HIV-1 nucleotide reverse transcriptase inhibitors (NtRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs), respectively.","indications":["Treatment of HIV-1 infection in adults with no antiretroviral treatment history or with viral suppression on a stable antiretroviral regimen for at least 6 months"],"catalyst":""},{"name":"Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate","genericName":"Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate","slug":"doravirine-lamivudine-tenofovir-disoproxil-fumarate","phase":"phase_3","mechanism":"This combination drug inhibits HIV reverse transcriptase and integrase to block viral replication and reduce HIV viral load.","indications":["HIV-1 infection in treatment-naïve adults","HIV-1 infection in treatment-experienced adults"],"catalyst":""},{"name":"Dose-matched Placebo to Suvorexant","genericName":"Dose-matched Placebo to Suvorexant","slug":"dose-matched-placebo-to-suvorexant","phase":"phase_3","mechanism":"This is a placebo control formulation matched to suvorexant, an orexin receptor antagonist used to promote sleep.","indications":["Insomnia (sleep onset and/or sleep maintenance) — placebo control in phase 3 trials"],"catalyst":""},{"name":"Doxorubicin (A)","genericName":"Doxorubicin (A)","slug":"doxorubicin-a","phase":"phase_3","mechanism":"Doxorubicin intercalates into DNA and inhibits topoisomerase II, preventing DNA replication and transcription in cancer cells.","indications":["Breast cancer","Lymphomas (Hodgkin and non-Hodgkin)","Acute leukemias","Ovarian cancer","Bladder cancer"],"catalyst":""},{"name":"EMEND","genericName":"EMEND","slug":"emend","phase":"marketed","mechanism":"EMEND (aprepitant) blocks substance P neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.","indications":["Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","Prevention of postoperative nausea and vomiting (PONV)"],"catalyst":""},{"name":"ER-niacin","genericName":"ER-niacin","slug":"er-niacin","phase":"phase_3","mechanism":"ER-niacin is an extended-release formulation of niacin (vitamin B3) that raises HDL cholesterol and lowers triglycerides and LDL cholesterol.","indications":["Dyslipidemia; elevated triglycerides and low HDL cholesterol in patients at risk for cardiovascular disease"],"catalyst":""},{"name":"Elestat","genericName":"Elestat","slug":"elestat","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Emetogenic chemotherapy","genericName":"Emetogenic chemotherapy","slug":"emetogenic-chemotherapy","phase":"phase_3","mechanism":"Emetogenic chemotherapy refers to chemotherapy agents that induce nausea and vomiting as a side effect, rather than a drug with a specific anti-emetic mechanism.","indications":["Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving emetogenic chemotherapy"],"catalyst":""},{"name":"Enclitide Chloride","genericName":"Enclitide Chloride","slug":"enclitide-chloride","phase":"phase_2","mechanism":"Enclitide chloride is a chloride channel blocker.","indications":["Treatment of chemotherapy-induced neuropathic pain"],"catalyst":""},{"name":"Glimepiride 2 mg","genericName":"Glimepiride 2 mg","slug":"glimepiride-2-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glimepiride or gliclazide","genericName":"Glimepiride or gliclazide","slug":"glimepiride-or-gliclazide","phase":"phase_3","mechanism":"Glimepiride and gliclazide stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Glimerpiride","genericName":"Glimerpiride","slug":"glimerpiride","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"H1 Receptor Antagonist","genericName":"H1 Receptor Antagonist","slug":"h1-receptor-antagonist","phase":"phase_3","mechanism":"H1 receptor antagonists block histamine binding to H1 receptors, reducing histamine-mediated allergic and inflammatory responses.","indications":["Allergic rhinitis","Urticaria","Allergic reactions","Pruritus"],"catalyst":""},{"name":"H2 Receptor Antagonist","genericName":"H2 Receptor Antagonist","slug":"h2-receptor-antagonist","phase":"phase_3","mechanism":"H2 receptor antagonists block histamine H2 receptors on gastric parietal cells to reduce stomach acid secretion.","indications":["Peptic ulcer disease","Gastroesophageal reflux disease (GERD)","Zollinger-Ellison syndrome"],"catalyst":""},{"name":"IMI/REL FDC","genericName":"IMI/REL FDC","slug":"imi-rel-fdc","phase":"phase_3","mechanism":"IMI/REL is a fixed-dose combination of imipenem (a carbapenem antibiotic) and relebactam (a beta-lactamase inhibitor) that works together to overcome bacterial resistance mechanisms.","indications":["Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria","Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible gram-negative bacteria"],"catalyst":""},{"name":"INS365 Ophthalmic Solution","genericName":"INS365 Ophthalmic Solution","slug":"ins365-ophthalmic-solution","phase":"phase_3","mechanism":"INS365 is a small-molecule selective inhibitor of inositol 1,4,5-trisphosphate (IP3) receptors that reduces intracellular calcium signaling in ocular surface cells.","indications":["Dry eye disease (keratoconjunctivitis sicca)"],"catalyst":""},{"name":"IV Tulisokibart","genericName":"IV Tulisokibart","slug":"iv-tulisokibart","phase":"phase_3","mechanism":"Tulisokibart is a TLR7 agonist that activates innate immune responses to enhance anti-tumor immunity.","indications":["Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"IV golimumab","genericName":"IV golimumab","slug":"iv-golimumab","phase":"phase_3","mechanism":"Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Ulcerative colitis","Crohn's disease"],"catalyst":""},{"name":"Insulin Glargine Rescue Medication","genericName":"Insulin Glargine Rescue Medication","slug":"insulin-glargine-rescue-medication","phase":"phase_3","mechanism":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues while suppressing hepatic glucose production.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus (as rescue or intensification therapy)"],"catalyst":""},{"name":"L50/H12.5","genericName":"L50/H12.5","slug":"l50-h12-5","phase":"phase_3","mechanism":"L50/H12.5 is a fixed-dose combination of losartan and hydrochlorothiazide that reduces blood pressure by blocking angiotensin II receptors and inhibiting sodium reabsorption in the kidney.","indications":["Hypertension"],"catalyst":""},{"name":"L50/H12.5/A5","genericName":"L50/H12.5/A5","slug":"l50-h12-5-a5","phase":"phase_3","mechanism":"L50/H12.5/A5 is a fixed-dose combination of three antihypertensive agents that work synergistically to reduce blood pressure through multiple pathways.","indications":["Hypertension in patients requiring triple antihypertensive therapy"],"catalyst":""},{"name":"Leader Antacid","genericName":"Leader Antacid","slug":"leader-antacid","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Letermovir IV","genericName":"Letermovir IV","slug":"letermovir-iv","phase":"phase_3","mechanism":"Letermovir inhibits the viral terminase enzyme of cytomegalovirus (CMV), preventing viral DNA packaging and replication.","indications":["CMV prophylaxis in CMV-seronegative recipients of allogeneic hematopoietic stem cell transplant from CMV-seropositive donors","CMV infection and disease in immunocompromised patients (treatment)"],"catalyst":""},{"name":"Letermovir intravenous","genericName":"Letermovir intravenous","slug":"letermovir-intravenous","phase":"phase_2","mechanism":"Inhibits human cytomegalovirus (HCMV) replication by targeting the viral terminase complex","indications":["Prevention of cytomegalovirus (CMV) infection in adult recipients of an allogeneic hematopoietic stem cell transplant"],"catalyst":""},{"name":"Leucovorin/levofolinate calcium","genericName":"Leucovorin/levofolinate calcium","slug":"leucovorin-levofolinate-calcium","phase":"phase_3","mechanism":"Leucovorin is a reduced form of folic acid that replenishes intracellular folate pools and enhances the cytotoxic effects of fluorouracil and other antifolate drugs.","indications":["Metastatic colorectal cancer (in combination with 5-fluorouracil)","Rescue agent for high-dose methotrexate therapy","Adjuvant in fluorouracil-based chemotherapy regimens"],"catalyst":""},{"name":"M-M-RTM II","genericName":"M-M-RTM II","slug":"m-m-rtm-ii","phase":"marketed","mechanism":"M-M-R II is a live attenuated viral vaccine that stimulates immune responses against measles, mumps, and rubella by introducing weakened forms of these viruses.","indications":["Prevention of measles, mumps, and rubella in children and adults"],"catalyst":""},{"name":"MK-0518","genericName":"MK-0518","slug":"mk-0518","phase":"phase_3","mechanism":"MK-0518 is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","HIV-1 infection in combination antiretroviral therapy"],"catalyst":""},{"name":"MK-0822","genericName":"MK-0822","slug":"mk-0822","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-0873 2% Cream","genericName":"MK-0873 2% Cream","slug":"mk-0873-2-cream","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-1006 FCT","genericName":"MK-1006 FCT","slug":"mk-1006-fct","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-1075","genericName":"MK-1075","slug":"mk-1075","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-1084","genericName":"MK-1084","slug":"mk-1084","phase":"phase_3","mechanism":"MK-1084 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.","indications":["Chronic pain conditions (investigational)","Chemotherapy-induced nausea and vomiting (CINV) (investigational)"],"catalyst":""},{"name":"MK-1293","genericName":"MK-1293","slug":"mk-1293","phase":"phase_3","mechanism":"MK-1293 is a glucagon receptor antagonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"MK-2214","genericName":"MK-2214","slug":"mk-2214","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MK-3475A","genericName":"MK-3475A","slug":"mk-3475a","phase":"phase_3","mechanism":"MK-3475A is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and its ligands, thereby enhancing anti-tumor immune responses.","indications":["Advanced or metastatic melanoma","Non-small cell lung cancer","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Gastric or gastroesophageal junction adenocarcinoma"],"catalyst":""},{"name":"MK-4082","genericName":"MK-4082","slug":"mk-4082","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-4305 40 mg","genericName":"MK-4305 40 mg","slug":"mk-4305-40-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-4618","genericName":"MK-4618","slug":"mk-4618","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-4646","genericName":"MK-4646","slug":"mk-4646","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-4700","genericName":"MK-4700","slug":"mk-4700","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MK-5478","genericName":"MK-5478","slug":"mk-5478","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-6072","genericName":"MK-6072","slug":"mk-6072","phase":"phase_3","mechanism":"MK-6072 is a glucokinase activator that enhances glucose sensing and insulin secretion in pancreatic beta cells.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"MK-6837","genericName":"MK-6837","slug":"mk-6837","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MK-6916","genericName":"MK-6916","slug":"mk-6916","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-7252","genericName":"MK-7252","slug":"mk-7252","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8150 100 mg","genericName":"MK-8150 100 mg","slug":"mk-8150-100-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8150 120 mg","genericName":"MK-8150 120 mg","slug":"mk-8150-120-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8150 160 mg","genericName":"MK-8150 160 mg","slug":"mk-8150-160-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8150 600 mg","genericName":"MK-8150 600 mg","slug":"mk-8150-600-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8266 BID, 1.8 mg","genericName":"MK-8266 BID, 1.8 mg","slug":"mk-8266-bid-1-8-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8266 TID, 2.4 mg","genericName":"MK-8266 TID, 2.4 mg","slug":"mk-8266-tid-2-4-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8504","genericName":"MK-8504","slug":"mk-8504","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8507","genericName":"MK-8507","slug":"mk-8507","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8527","genericName":"MK-8527","slug":"mk-8527","phase":"phase_3","mechanism":"MK-8527 is a selective inhibitor of menin that restores wild-type p53 function in TP53-mutant cancers by disrupting the menin-MLL interaction.","indications":["Acute myeloid leukemia (AML) with TP53 mutations","Acute lymphoblastic leukemia (ALL) with TP53 mutations"],"catalyst":""},{"name":"MK-8558","genericName":"MK-8558","slug":"mk-8558","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8591A","genericName":"MK-8591A","slug":"mk-8591a","phase":"phase_3","mechanism":"MK-8591A is a nucleoside reverse transcriptase translocation inhibitor (NRTI) that blocks HIV reverse transcriptase by preventing the translocation of the enzyme along the viral RNA template.","indications":["HIV-1 infection (treatment-experienced and treatment-naive patients)"],"catalyst":""},{"name":"MK-8616","genericName":"MK-8616","slug":"mk-8616","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK-8931","genericName":"MK-8931","slug":"mk-8931","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0249","genericName":"MK0249","slug":"mk0249","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0364","genericName":"MK0364","slug":"mk0364","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0524","genericName":"MK0524","slug":"mk0524","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0524A, /Duration of Treatment : 4 Weeks","genericName":"MK0524A, /Duration of Treatment : 4 Weeks","slug":"mk0524a-duration-of-treatment-4-weeks","phase":"phase_3","mechanism":"MK0524A is a niacin receptor agonist that activates GPR109A to raise HDL cholesterol and lower triglycerides.","indications":["Dyslipidemia with low HDL-cholesterol and/or elevated triglycerides"],"catalyst":""},{"name":"MK0752","genericName":"MK0752","slug":"mk0752","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0773","genericName":"MK0773","slug":"mk0773","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0826; ertapenem sodium","genericName":"MK0826; ertapenem sodium","slug":"mk0826-ertapenem-sodium","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0831","genericName":"MK0831","slug":"mk0831","phase":"phase_3","mechanism":"MK0831 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells and other immune cells to the tumor microenvironment.","indications":["Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"MK0869, aprepitant","genericName":"MK0869, aprepitant","slug":"mk0869-aprepitant","phase":"phase_3","mechanism":"Aprepitant is a selective antagonist of neurokinin-1 (NK1) receptors that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center of the brain.","indications":["Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy","Post-operative nausea and vomiting (PONV) prevention"],"catalyst":""},{"name":"MK0966 / Duration of Treatment: 1 Days","genericName":"MK0966 / Duration of Treatment: 1 Days","slug":"mk0966-duration-of-treatment-1-days","phase":"phase_3","mechanism":"MK0966 is a selective COX-2 inhibitor that reduces prostaglandin production to decrease inflammation and pain.","indications":["Acute pain","Rheumatoid arthritis","Osteoarthritis","Ankylosing spondylitis"],"catalyst":""},{"name":"MK0966; rofecoxib","genericName":"MK0966; rofecoxib","slug":"mk0966-rofecoxib","phase":"marketed","mechanism":"Rofecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain.","indications":["Osteoarthritis","Rheumatoid arthritis","Acute pain","Dysmenorrhea"],"catalyst":""},{"name":"MK0974 Ethanolate formulation","genericName":"MK0974 Ethanolate formulation","slug":"mk0974-ethanolate-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK8245","genericName":"MK8245","slug":"mk8245","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MMRV (2006 process)","genericName":"MMRV (2006 process)","slug":"mmrv-2006-process","phase":"phase_3","mechanism":"MMRV is a live attenuated combination vaccine that provides immunization against measles, mumps, rubella, and varicella by stimulating immune responses to all four viruses.","indications":["Prevention of measles, mumps, rubella, and varicella in children aged 12 months and older"],"catalyst":""},{"name":"MMRV (AMP)","genericName":"MMRV (AMP)","slug":"mmrv-amp","phase":"phase_3","mechanism":"MMRV is a live attenuated combination vaccine that provides immunization against measles, mumps, rubella, and varicella by stimulating adaptive immune responses to all four viruses.","indications":["Prevention of measles, mumps, rubella, and varicella in children"],"catalyst":""},{"name":"Matching Placebo for V114","genericName":"Matching Placebo for V114","slug":"matching-placebo-for-v114","phase":"phase_3","mechanism":"This is a placebo control formulation with no active pharmaceutical ingredient, used as a comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Matching Placebo for V116","genericName":"Matching Placebo for V116","slug":"matching-placebo-for-v116","phase":"phase_3","mechanism":"This is a placebo control formulation with no active pharmaceutical ingredient, used as a comparator in clinical trials for V116.","indications":[],"catalyst":""},{"name":"Matching Placebo to Sita/Met FDC","genericName":"Matching Placebo to Sita/Met FDC","slug":"matching-placebo-to-sita-met-fdc","phase":"phase_3","mechanism":"Sita/Met FDC combines sitagliptin, a dipeptidyl peptidase-4 inhibitor, with metformin, a biguanide, to improve glycemic control in patients with type 2 diabetes.","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"Matching placebo to dapagliflozin","genericName":"Matching placebo to dapagliflozin","slug":"matching-placebo-to-dapagliflozin","phase":"phase_3","mechanism":"This is a matching placebo control arm, not an active drug; it contains no pharmacologically active ingredient.","indications":[],"catalyst":""},{"name":"Matching placebo to glimepiride","genericName":"Matching placebo to glimepiride","slug":"matching-placebo-to-glimepiride","phase":"marketed","mechanism":"This is a placebo formulation designed to match the appearance and characteristics of glimepiride for use in clinical trials.","indications":["Clinical trial comparator for glimepiride efficacy and safety studies"],"catalyst":""},{"name":"Matching placebo to omarigliptin","genericName":"Matching placebo to omarigliptin","slug":"matching-placebo-to-omarigliptin","phase":"phase_3","mechanism":"Omarigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to stimulate insulin secretion and reduce glucagon in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Matching placebo to pioglitazone","genericName":"Matching placebo to pioglitazone","slug":"matching-placebo-to-pioglitazone","phase":"phase_3","mechanism":"This is a placebo control arm matching pioglitazone, a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.","indications":["Type 2 diabetes mellitus (placebo control in phase 3 trial)"],"catalyst":""},{"name":"Matching placebo to sitagliptin","genericName":"Matching placebo to sitagliptin","slug":"matching-placebo-to-sitagliptin","phase":"phase_3","mechanism":"This is a matching placebo control arm, not an active drug; it contains no pharmacologically active ingredient.","indications":["Control arm in phase 3 trial of sitagliptin for type 2 diabetes mellitus"],"catalyst":""},{"name":"Metformin - Rescue","genericName":"Metformin - Rescue","slug":"metformin-rescue","phase":"phase_3","mechanism":"Metformin reduces hepatic glucose production and improves insulin sensitivity to lower blood glucose levels in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Metformn","genericName":"Metformn","slug":"metformn","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Modified Process Hepatitis B Vaccine","genericName":"Modified Process Hepatitis B Vaccine","slug":"modified-process-hepatitis-b-vaccine","phase":"phase_3","mechanism":"This vaccine stimulates the immune system to produce antibodies against hepatitis B surface antigen, providing protection against hepatitis B virus infection.","indications":["Prevention of hepatitis B infection in infants, children, and adults"],"catalyst":""},{"name":"NeisVac-C®","genericName":"NeisVac-C®","slug":"neisvac-c","phase":"marketed","mechanism":"NeisVac-C is a meningococcal serogroup C conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C.","indications":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C in infants, children, adolescents, and adults"],"catalyst":""},{"name":"Neostigmine + Glycopyrrolate","genericName":"Neostigmine + Glycopyrrolate","slug":"neostigmine-glycopyrrolate","phase":"marketed","mechanism":"Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to prevent cholinergic side effects.","indications":["Reversal of neuromuscular blockade induced by non-depolarizing neuromuscular blocking agents"],"catalyst":""},{"name":"Normale Saline Solution","genericName":"Normale Saline Solution","slug":"normale-saline-solution","phase":"phase_3","mechanism":"Normal saline solution provides isotonic fluid replacement and electrolyte balance by delivering 0.9% sodium chloride in water to match physiological osmolarity.","indications":["Fluid resuscitation and volume replacement in dehydration","Maintenance of electrolyte balance in hospitalized patients","Vehicle for intravenous drug administration"],"catalyst":""},{"name":"Open-label Glimepiride","genericName":"Open-label Glimepiride","slug":"open-label-glimepiride","phase":"phase_3","mechanism":"Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Open-label Metformin","genericName":"Open-label Metformin","slug":"open-label-metformin","phase":"phase_3","mechanism":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Oral Suspension Tedizolid Phosphate","genericName":"Oral Suspension Tedizolid Phosphate","slug":"oral-suspension-tedizolid-phosphate","phase":"marketed","mechanism":"Tedizolid phosphate is a prodrug that is converted to tedizolid, an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.","indications":["Acute bacterial skin and skin structure infections (ABSSSI)","Community-acquired bacterial pneumonia (CABP)"],"catalyst":""},{"name":"Org 50081","genericName":"Org 50081","slug":"org-50081","phase":"phase_3","mechanism":"Org 50081 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.","indications":["Muscle wasting or sarcopenia (investigational)"],"catalyst":""},{"name":"PEG-IFN alfa-2b","genericName":"PEG-IFN alfa-2b","slug":"peg-ifn-alfa-2b","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PENTACEL™","genericName":"PENTACEL™","slug":"pentacel","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"PLD, cyclophosphamide, trastuzumab, paclitaxel","genericName":"PLD, cyclophosphamide, trastuzumab, paclitaxel","slug":"pld-cyclophosphamide-trastuzumab-paclitaxel","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PPI","genericName":"PPI","slug":"ppi","phase":"marketed","mechanism":"PPIs inhibit the proton pump (H+/K+-ATPase) in gastric parietal cells to reduce gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Prevention of NSAID-induced ulcers"],"catalyst":""},{"name":"Paclitaxel (X)","genericName":"Paclitaxel (X)","slug":"paclitaxel-x","phase":"phase_3","mechanism":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic carcinoma of the ovary","Breast cancer (metastatic and adjuvant)","Non-small cell lung cancer","Kaposi's sarcoma","Gastric adenocarcinoma"],"catalyst":""},{"name":"PegIFN-2b","genericName":"PegIFN-2b","slug":"pegifn-2b","phase":"marketed","mechanism":"PegIFN-2b is a pegylated interferon-beta that activates interferon-beta receptors to enhance innate and adaptive immune responses against viral infections and certain malignancies.","indications":["Chronic hepatitis C (in combination with ribavirin)","Multiple sclerosis (relapsing-remitting forms)"],"catalyst":""},{"name":"Peginterferon alfa-2b (PEG)","genericName":"Peginterferon alfa-2b (PEG)","slug":"peginterferon-alfa-2b-peg","phase":"phase_3","mechanism":"Peginterferon alfa-2b is a pegylated form of interferon alfa-2b that enhances and prolongs immune activation by binding to interferon-alpha receptors on immune cells.","indications":["Chronic hepatitis C (in combination with ribavirin)","Chronic hepatitis B","Melanoma (adjuvant therapy)"],"catalyst":""},{"name":"Peginterferon alfa-2b (PEG2b)","genericName":"Peginterferon alfa-2b (PEG2b)","slug":"peginterferon-alfa-2b-peg2b","phase":"phase_3","mechanism":"Peginterferon alfa-2b (PEG2b) is a pegylated form of interferon alfa-2b, which works by stimulating the body's immune system to fight viral infections.","indications":["Chronic hepatitis C","Chronic hepatitis B"],"catalyst":""},{"name":"Pegylated Lyposomal Doxorubicin","genericName":"Pegylated Lyposomal Doxorubicin","slug":"pegylated-lyposomal-doxorubicin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pembrolizumab (K)","genericName":"Pembrolizumab (K)","slug":"pembrolizumab-k","phase":"phase_3","mechanism":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, preventing tumor cells from evading immune attack.","indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""},{"name":"Pembrolizumab Formulated with Berahyaluronidase Alfa","genericName":"Pembrolizumab Formulated with Berahyaluronidase Alfa","slug":"pembrolizumab-formulated-with-berahyaluronidase-alfa","phase":"phase_3","mechanism":"Pembrolizumab blocks PD-1 on immune cells to restore anti-tumor immunity, while berahyaluronidase alfa enhances subcutaneous drug delivery by temporarily degrading hyaluronic acid in tissue.","indications":["Melanoma (advanced or metastatic)","Non-small cell lung cancer (metastatic, PD-L1 positive)","Head and neck squamous cell carcinoma","Hodgkin lymphoma (classical, relapsed or refractory)","Gastric or gastroesophageal junction adenocarcinoma"],"catalyst":""},{"name":"Pembrolizumab IV","genericName":"Pembrolizumab IV","slug":"pembrolizumab-iv","phase":"phase_3","mechanism":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, preventing tumor cells from evading immune attack.","indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""},{"name":"Pembrolizumab SC","genericName":"Pembrolizumab SC","slug":"pembrolizumab-sc","phase":"phase_3","mechanism":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.","indications":["Metastatic non-small cell lung cancer (NSCLC)","Melanoma","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""},{"name":"Pembrolizumab placebo (saline)","genericName":"Pembrolizumab placebo (saline)","slug":"pembrolizumab-placebo-saline","phase":"phase_3","mechanism":"This is a saline placebo control with no active pharmacological mechanism.","indications":["Control arm in pembrolizumab phase 3 clinical trials"],"catalyst":""},{"name":"Pembrolizumab/Quavonlimab","genericName":"Pembrolizumab/Quavonlimab","slug":"pembrolizumab-quavonlimab","phase":"phase_3","mechanism":"Pembrolizumab/Quavonlimab is a combination of a PD-1 inhibitor and a TIGIT inhibitor, which works by blocking the PD-1 and TIGIT proteins to enhance the body's immune response against cancer cells.","indications":["Locally advanced or metastatic non-small cell lung cancer","Locally advanced or metastatic small cell lung cancer"],"catalyst":""},{"name":"Pembrolizumab/Vibostolimab","genericName":"Pembrolizumab/Vibostolimab","slug":"pembrolizumab-vibostolimab","phase":"phase_3","mechanism":"Pembrolizumab blocks PD-1 to enhance T-cell immunity, while vibostolimab blocks VISTA to further relieve immune suppression in the tumor microenvironment.","indications":["Advanced or metastatic melanoma","Non-small cell lung cancer"],"catalyst":""},{"name":"Pembrolizumab/Vibostolimab Co-Formulation","genericName":"Pembrolizumab/Vibostolimab Co-Formulation","slug":"pembrolizumab-vibostolimab-co-formulation","phase":"phase_3","mechanism":"Pembrolizumab/Vibostolimab Co-Formulation is a PD-1/PD-L1 inhibitor that works by blocking the PD-1/PD-L1 interaction, thereby enhancing the body's immune response against cancer cells.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Pioglitazone rescue therapy","genericName":"Pioglitazone rescue therapy","slug":"pioglitazone-rescue-therapy","phase":"phase_3","mechanism":"Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in patients with type 2 diabetes.","indications":["Type 2 diabetes mellitus (rescue/add-on therapy)"],"catalyst":""},{"name":"Placebo - 0.9% w/v sodium chloride solution","genericName":"Placebo - 0.9% w/v sodium chloride solution","slug":"placebo-0-9-w-v-sodium-chloride-solution","phase":"phase_3","mechanism":"0.9% sodium chloride solution is an isotonic saline that serves as a physiologically inert vehicle for drug delivery or as a control comparator in clinical trials.","indications":["Placebo control in Phase 3 clinical trials"],"catalyst":""},{"name":"Placebo for Aprepitant PFS","genericName":"Placebo for Aprepitant PFS","slug":"placebo-for-aprepitant-pfs","phase":"phase_3","mechanism":"This is a placebo control with no active pharmacological mechanism.","indications":["Control arm in clinical trials for aprepitant efficacy and safety evaluation"],"catalyst":""},{"name":"Placebo for Enlicitide","genericName":"Placebo for Enlicitide","slug":"placebo-for-enlicitide","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trial for Enlicitide"],"catalyst":""},{"name":"Placebo for Glipizide","genericName":"Placebo for Glipizide","slug":"placebo-for-glipizide","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Control arm in Phase 3 clinical trial for Glipizide efficacy in type 2 diabetes"],"catalyst":""},{"name":"Placebo for Rosuvastatin","genericName":"Placebo for Rosuvastatin","slug":"placebo-for-rosuvastatin","phase":"phase_3","mechanism":"Rosuvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis.","indications":["Hypercholesterolemia","Hyperlipidemia"],"catalyst":""},{"name":"Placebo for Sitagliptin","genericName":"Placebo for Sitagliptin","slug":"placebo-for-sitagliptin","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Control arm in Phase 3 clinical trial for Sitagliptin (type 2 diabetes mellitus)"],"catalyst":""},{"name":"Placebo for V110","genericName":"Placebo for V110","slug":"placebo-for-v110","phase":"phase_3","mechanism":"A placebo control arm contains no active pharmaceutical ingredient and serves as a comparator in clinical trials.","indications":["Control arm in V110 clinical trial (indication for V110 unknown)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNdGZiTmRtbndHdDNCNXd4VThZV1BKd0pWLVNPMzMwNmF5ZnhsMTRENWNsTVNhampGSXF4LVhCZF9VQ2RzRzdQM2Y0dVlPV09YWXo1WUZKSnByM1RrbWxHNU1uRXNmaVhkTUg0eWlvY3pMRWVmNkF3bXNmSXZaXzE3NlRZbmJhSU9iM2xKTkFhdUVYMklMdy1sZExCRHdHUUZPWEV1MkxReTByZ2dHRkJZeTU5VnNiWFhiTnQ1cw?oc=5","date":"2026-04-07","type":"deal","source":"Stock Titan","summary":"Merck (NYSE: TERN) to acquire Terns for $53.00 per share cash - Stock Titan","headline":"Merck (NYSE: TERN) to acquire Terns for $53.00 per share cash","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOZUVfV0VNSzdxRFVIdzNCLUtGdUI5ZHNCVjgzMXp0aFF4eXdPZnU0WWwtNl9HQmtlV0MzYTJrV3Nlbmpad1dOdGZ4RWR5ajAtZ3NWeXV2VVBiSmNaRXZ2OWVWRG81M3VJSWxwMDhWQmIwaXVwZXdFRWRmdjBrbjZIVmpWLXcwN3VKcExibzQycHhLbG5sMjFfbi1wZ01uekVUekZaN1pQMmZvMnFfNmR6bVhR?oc=5","date":"2026-03-30","type":"deal","source":"Stock Titan","summary":"Merck to buy Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in cash - Stock Titan","headline":"Merck to buy Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in cash","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQcnFDWUhqRDVDaWZ6Z0JQX3ZJZEdlQlhDUFBEMDBiNldCckszQ012bW1KMHJyVWJfWExMMmhxWDZtN3d3SkUxc1pnM0dLTHc5QktfVlhtelY0N3NYeFM0aDM1VS1nODl0eUdrTGdCQktQRW02QkxReXVURm5LbFk4SjlfQUx1dGl2bFJZN0JlY3c0TjlOaEQ4NmRmUmxFOVI5RUtua19lTWdJV3lXck11b2RpSDdQTlNLMUxQcGxKcw?oc=5","date":"2026-03-25","type":"deal","source":"Stock Titan","summary":"Merck (TERN) plans tender offer to acquire Terns under March 24, 2025 merger - Stock Titan","headline":"Merck (TERN) plans tender offer to acquire Terns under March 24, 2025 merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPS3VNanRLNWtia3V0cnZQZTdpUnJHYllYYVJHMGJyNjBuOGpuMUFma2tybGlSM2tDWmNsV05jTU9WQVNydXpqMzRzZWtCaW92bmY2aVV3XzNwTDc0TzBodmJaNTF3X1l1ZG92RGMtblltNlhXSDRTaEs3RjdnSlVEQUF0UFpqeEpad3k1b2ZGSjdnQndNOGtqbXVR?oc=5","date":"2026-03-18","type":"pipeline","source":"openPR.com","summary":"Hodgkin's Lymphoma Pipeline Expands as 15+ Pharma Companies - openPR.com","headline":"Hodgkin's Lymphoma Pipeline Expands as 15+ Pharma Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxOWmdoSVZTdVhrc3VVWXlRWHdpT2l0Y3ZYSDBld0V5VlEwX1lEenNkNlBBMEI0X19WVVYxdGFuOWY3VzlLek5zbXBmVGVZMFFHamp5bFB0dmctLWs2RTRUQVM3eXFlLURMMW1kcUdvUllvUDVqRjJQR3ppRzI0SXRsZExxSGdiSFNaeGJpOGpqXzIwSEFUQ0dxdko5RFBUcWJUdHNzaWFiM2FaQ2lGdlBrVTV2V2RVaXgwRDNuX01ZdmFaQ05PNDZqdjRrT2hYaWxyZFk4d1FNUFdkQTlUYUZEU2sxaGh5ZkQxeTlTQ1dsQm1HQUhnX2JHTWE2Yw?oc=5","date":"2026-03-05","type":"trial","source":"Barchart.com","summary":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQVEV3MjFKV0FqYU9zTFZOblFPamV5MXBlMVZEcWlCVHJsTElNcTUwZHFfcGZVSW5sVHF6Q2xBOEVINkgwVmd5Y1d6VjZhSHFNLTVSV3NnRmFqeC1Sek9UMEw3S21abGhKY0NBT0ZTeHFwR0lKZXkzVlJjT0IwSzFKemJaSHl1anRCN0RXTXdpdF9OalRkQWZJQUwxMGRYNWhqSzFSaHN3?oc=5","date":"2026-01-06","type":"pipeline","source":"WALB","summary":"WALB Investigates: Merck moves to dismiss Flint River Plant cancer lawsuit - WALB","headline":"WALB Investigates: Merck moves to dismiss Flint River Plant cancer lawsuit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBGX3ZaVzlkWWlBaWFRbDdfMVVlT2JKVFdKc0RyQUZmNG9ZUjd0ZFlPd1REcHdNRHVhMWZyazU5a3dNaW1EdTBhdmJndkNjYWIzQjZjU29jc1hHN1FTX2c?oc=5","date":"2025-11-17","type":"trial","source":"Claim Depot","summary":"Merck Data Breach: Financial Account Information Exposed - Claim Depot","headline":"Merck Data Breach: Financial Account Information Exposed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNdjRSQ044M1g0VmJ1bXdRSnZGRkxaODdBOW83YXZKbWlOcG53SVd1dWppUzFCOW9teUozMXJpVGV6X3RCbkZCQkRudGVGR1hmdW56dUZYTXYwLUNGMEtRaWJmbXZSRWJ6bWZzanhpRmw3bld4QThaNDZISGtGaXc5eWRxeUNDZkRmc3MzSEY0RGVCdWJpWXN2S2l0VFJsSi1OUWc?oc=5","date":"2025-10-17","type":"regulatory","source":"lupin.com","summary":"Lupin Receives Tentative Approval from U.S. FDA for Letermovir Tablets - lupin.com","headline":"Lupin Receives Tentative Approval from U.S. FDA for Letermovir Tablets","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQcHExN0RmSlZWUDY0aXhma3I4aXpYOWRBWEJta3pSR19HMGlHTUE3WnBNNkphTEJRUWFBNGZBQzYtd0h0ZjNFQ2VLS21HVDRCbDVkSm1BQVB2QkV5bjgyTllERnhHbjJ5blVOQ19lMGpFbHBTUGNuY0ktYV9TVTZ5NU1Zck9qTmxheHJJRVRpOFJyZWhaY0Fma1lMYVBVUGdrTnh4QV9pdjdNbEYzTGVxY0cyWnRUYTcxOXp0c1BBT2xnTEtPcllwQ0dDUzFhQQ?oc=5","date":"2025-10-07","type":"pipeline","source":"Investing.com","summary":"Merck completes acquisition of Verona Pharma; VRNA shares delisted from Nasdaq - Investing.com","headline":"Merck completes acquisition of Verona Pharma; VRNA shares delisted from Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPMjJzemhwLXlvQnNRLWdWd1ViR1BXUS1jZGZHd2wxZ1llaV8xQlVUYjF3d1VOX0F5dFcyUEFPMGcyb0hsNG9uVXhJMUNBd1N5anpya2ZDWURZSlRNcnd5bEdrYTl3UHFQVzN2NDA0WVRmYkE4cGNIYk4ydHZIbS1Rdy1jek9leFdyazNabVNQWUnSAVZBVV95cUxNWkh0MlF6Vk5vVm92U1A5YjdudEtzS2RxU0Jab1gyOFZvN24xVmtNVFU0VTNUZk1tWGR1UHhZd2dFZ0RZWUMxY2xSNzViR3I3dFBxTFprQQ?oc=5","date":"2025-09-19","type":"pipeline","source":"Law360","summary":"US-Based MSD Must Pay £6M For Use Of 'Merck' In UK - Law360","headline":"US-Based MSD Must Pay £6M For Use Of 'Merck' In UK - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNNng0VFRxeDdReTMzNWZUSFNfUEF6OGo1Wml2YmpWVUpKVHJ1QXoxQ3UyTnFTLWNCTmtSWFZaYlI0WXkxZVEtb2g4M1d3NUpvUHFHR0FFS1ZkWlQ1ZVgwb084WkdLZU1KR1lYbVVOdG1DbDdGSm5MVFhuZUVacEV6aHVmWnNDUTdjNlRseXM3cVdTZVRIRHVVbmVqRWNvbThkVHlSQl9aNFpmM3FIYWZYVFdWYWQ0WTdrU0N3SGZR?oc=5","date":"2025-07-10","type":"pipeline","source":"marketscreener.com","summary":"Merck Sharp & Dohme LLC completed the acquisition of Verona Pharma plc. - marketscreener.com","headline":"Merck Sharp & Dohme LLC completed the acquisition of Verona Pharma plc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPZEQ4Zm8tNU5zZnc4U3ZaaFJGTzJtd1FOcUwydU9LUFk4cVhWaXVUdVd6enVyeHoyQXRrNFMtQVU1bERxcy1keThXbmo3Y3hZdl9VV0hBZ0JqR3hiZkJoUVZvb3JXQ1pJeEJ4Z0llX1VKU1hfQWF4QUxpajAtLVpXSEtReHJoUQ?oc=5","date":"2025-02-26","type":"regulatory","source":"townsquaredelaware.com","summary":"Merck $900M Project Approved By Delaware Council - townsquaredelaware.com","headline":"Merck $900M Project Approved By Delaware Council","sentiment":"positive"},{"date":"2024-01-18","type":"earnings","source":"SEC EDGAR","summary":"SC 13D filed with SEC: SC 13D","headline":"SC 13D Filing","sentiment":"neutral"}],"patents":[],"drugCount":300,"phaseCounts":{"phase_3":162,"marketed":51,"phase_2":30,"phase_1":56,"discontinued":1},"enrichmentLevel":2,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":23643200000,"revenuePeriod":"2009-12-31","revenueHistory":[{"value":23643200000,"period":"2009-12-31"},{"value":23850300000,"period":"2008-12-31"},{"value":24197700000,"period":"2007-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":5139200000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":7952300000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":41749700000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}